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1 Abstract
The interaction of proteins with other proteins or small molecules is essential for bi-
ological functions. Understanding the molecular basis of protein-ligand binding is of
a vast interest for drug discovery, and computational methods to estimate protein-
ligand binding are starting to play an increasingly important role. In order to ap-
ply atomistic computational methods to the drug discovery process it is necessary
to have accurate three-dimensional structures of the target protein and a fast and
reliable method to estimate the binding affinity between the target protein and po-
tential inhibitors. Unfortunately, three-dimensional structures are not available for
all proteins of interest, but often their coordinates can be predicted by computational
methods such as homology modeling.
In this thesis we study the effect of inaccuracies of homologymodels to ligand bind-
ing using HIV-1 protease as a model system. Homology models of decreasing accu-
racy are built and additional errors are introduced by misplacing side chains during
rotamer modeling. We establish a MM-GBSA approach to estimate protein-ligand
binding free energies, and apply this method to the different homology models.
Although MM-GBSA methods are significantly faster than traditional MM-PBSA
methods, still the required computational effort is significant as it is based on the
calculation of a continuous molecular dynamics trajectory. In this study, we establish
a novel approach based on multiple independent short simulations, which is suitable
for execution of a distributed grid of computers and thereby dramatically reduces
the computation time needed. This workflow is validated using the HIV-1 protease
model system, and then applied to the estrogen receptor. Novel methods to assess the
sampling of the different trajectory approaches and potential application to docking
problems are presented and discussed.
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2 Overview
Proteins are organic macromolecules that are essential to all organisms. They are
comprised of amino acids linearly combined into polypeptides that fold into specific
three-dimensional structures. Proteins in cells perform a variety of tasks, ranging
from structural and mechanical functions such as in the cytoskeleton and in mus-
cles to controlling biological processes through interacting with other proteins or
small molecules that bind to them. Among biological processes that proteins control
through molecular recognition are cell signaling, signal transduction, immunologi-
cal responses and enzyme catalysis. The activity of proteins can often be modified
by the use of drugs that target specific interaction sites on the protein. This makes
the detailed understanding of the three-dimensional structure, the dynamics of pro-
teins and how they interact with their natural ligands and potential drugs essential
to aid the discovery and development of novel specific inhibitors for disease related
proteins in any drug discovery effort.
Ultimately it is the three-dimensional structure of proteins that determines their
function. In order to be able to accurately describe the interactions between proteins
and ligands a detailed three-dimensional structure of the protein is crucial. In spite
of considerable advances in the last decades, the mechanism in which proteins fold is
still not fully understood, and therefore the determination of a protein structure di-
rectly from its amino acid sequence is still not possible with computational methods.
The three-dimensional structures of proteins must therefore be determined experi-
mentally with methods such as x-ray crystallography, nuclear magnetic resonance
or cryo-electro microscopy. These methods, however, are slow in comparison to the
rapid accumulation of protein sequences that are being determined, which results
in a huge gap between known protein sequences and the actual three-dimensional
structures of the corresponding proteins. In those cases where no experimentally de-
termined three-dimensional structures are available, homology modeling methods
provide insights and are becoming increasingly important. Such methods are based
on the observation that the three-dimensional structures of proteins within a protein
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family are better conserved than their amino acid sequence1. This enables a three-
dimensional model of a protein sequence to be built based on its similarity to related
proteins with a known structure.
Drug discovery and development is a multi-billion dollar business and although
the numbers of actively pursued drug targets vary in the literature, the consensus
number is at least 324 drug targets that are currently being pursued2. In order to
identify potential drug leads, drug discovery makes use of methods such as high-
throughput screening, where large libraries of compounds are tested for their ability
to interact with the target protein. To reduce the number of compounds that have
to be synthesized and tested, computational methods such as virtual screening are
becoming increasingly important to the drug discovery process. In virtual screening
molecules from large libraries of available compounds are docked computationally
into the binding site of the protein target. To identify compounds that are poten-
tial drug leads, the binding energy between the protein and compounds is calculated
and those that have the most favorable interaction are selected for further analysis.
It is therefore very important to have a fast and reliable way of calculating these in-
teractions accurately. The drawback of such virtual screening methods is that the
algorithms currently used have to make a number of approximations in order to be
able to screen large numbers of compounds in a reasonable time, which results in less
accurate description of the binding energies.
One way to overcome these limitations is to use more accurate force field based
methods to determine the binding energies of the compounds and thereby more reli-
ably reject those poses that do not have a favorable binding energy. Such force field
methods have their limitations as well, in addition of requiring reliable force field
parameters for the calculations of interaction energies these methods tend to be very
computationally expensive which limits their applicability to the drug discovery pro-
cess.
In this thesis we aim to address some of the limitations of protein-ligand affinity cal-
culations: first by analyzing the usefulness of homology models for binding affinity
calculations or in other words how sensitive are these calculations to erroneous struc-
tures; then by modifying the molecular dynamics protocol to sample protein-ligand
conformations more efficiently and finally by addressing the question whether the
lowest scoring docking pose is necessarily the best one and if the poses can be im-
proved by running a molecular dynamics simulation on them.
This thesis is organized as follows: First, a general introduction to the acquire-
6
ment of protein and ligand coordinates, methods to estimate the binding energy and
ways to enhance conformational sampling is given, followed by a brief introduc-
tion to the protein systems used in this work. Second, the methods applied in this
work are introduced and described in detail. Finally, the main results are presented,
first the question of how inaccuracies in protein structure models affect the estimate
of protein-ligand interactions is addressed, and finally the development of multiple
short trajectory approach to speed up computationally intensive calculations is re-
ported.
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3 Introduction
3.1 Protein and Ligand Coordinates
In recent years molecular biology has moved from studying only one gene at a time,
to the study of whole genomes and biological systems3. Microarray and proteomic
methods help to identify disregulated genes and proteins that are abnormally ex-
pressed and with the assistance of bioinformatics tools an increasing amount of lead
compounds that could potentially be novel drug candidates are being identified4,5.
This has made molecular biology extremely important for drug discovery, not only
for the development of high-throughput assays and designing clinical trials, but also
for the identification of novel drug targets.
With this increase in identification of potential drug targets, computational meth-
ods of discovering likely drugs are becoming increasingly important. It is vital for
most virtual screeningmethods that an accurate and reliable three-dimensional struc-
ture of the target protein is available. Unfortunately, themechanism inwhich proteins
fold into their functional three-dimensional structures from the amino acid chain is
still poorly understood6. In spite of advances in ab initio prediction of protein struc-
tures directly from the amino acid sequence7 and through efforts of distributed com-
puting project such as Folding@home, the computational simulation of the folding of
proteins is still limited to small peptides and a very time-consuming process8. The
three-dimensional structures of proteins must therefore be determined experimen-
tally. Even though techniques such as x-ray crystallography, NMR spectroscopy and
cryo-electron microscopy are becoming faster, there is still a large gap between the
number of available structures and the protein sequences. In these cases where no
experimental structure exists, homology modeling proves to be an important alterna-
tive.
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3.1.1 Homology Modeling
In the SwissProt databases there are currently∼ 400.000 non-redundant annotated se-
quences9 and if the computer annotated TrEMBL database is included there are over
6.5million protein sequences available in these databases (http://www.expasy.ch/sprot).
In contrast, there are only around 53.000 proteins structures that have been solved ex-
perimentally10. There is obviously a huge gap between the available experimentally
determined structures and the sequences that have been determined.
Homology modeling (HM) is based on the observation that structures within a
given protein fold family are better conserved than their sequences1. This observation
enables known experimental structures to be used as a template protein to create a
three-dimensional model for a similar protein for which the structure is unknown, or
the target protein11. Figure 3.1 shows the four steps that are common to all methods
in building homology models.
Figure 3.1: The main steps involved in building a homology model.
In the first step the template protein is selected from the protein data bank (PDB)10,
using the target protein sequence as a query. Sequence similarity is a well established
10
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measure to select suitable template structures12. If the sequence similarity is high
(>30%) this is relatively straight forward with pairwise sequence comparison tools
such as BLAST13 and FASTA14 most commonly used for that task. However, if the
sequence identity between the target and template sequences is below 30% alternative
strategies based on multiple sequence alignment such as profile analysis15,16 have to
be used.
The second step involves aligning the target and template sequences. The align-
ment from the template selection is not necessarily the optimal one, because the al-
gorithms use to detect remote homologs are not necessarily the best ones for the best
possible alignment. Once a suitable template has been selected it should therefore be
aligned to the target using specialized programs such as t-coffee17. For closely related
proteins with sequence similarity over 50% this alignment is almost always correct.
However, if the sequence similarity falls below 35%, the so called "twilight zone" is
entered and the accuracy of the alignment drops significantly where regions of low
sequence similarity increase18. In general it can be assumed that as the sequence sim-
ilarity decreases the alignment contains increasing number of gaps and alignment
errors. Great care must therefore be taken to obtain an accurate alignment because
no modeling procedure can recover from incorrect alignment; consequently manual
inspection of the alignment is often required and strongly encouraged.
Based on the template structure(s) and the alignment between the target and tem-
plate(s), a model for the target sequence is built. To assist with the homology model-
ing, a number of automated methods are available. In general, they can be divided
in methods based on rigid fragment assembly such as SWISS-MODEL19,20 or Com-
poser21 and spatial restraint methods as used inModeller22. Modeling based on rigid
fragment assemblymakes use of the possibility to identify structurally conserved core
sections within a protein family that can be used to build the model. The loops and
side-chains are however variable and have to be modeled by other means. Mod-
eling by satisfaction of spatial restraints involves generating numerous constraints
or restraints on the structure of the target sequence based on bond lengths, angles,
dihedrals and non-bonded contacts that are obtained from a molecular mechanics
force fields. The models are built by minimizing the penalty of these restraints. Side-
chains are normally modeled using rotamer libraries23 which is often backbone de-
pendent24. Loop modeling is either based on ab initiomethods where a large number
of possible conformations are generated and scored25,26, or database methods which
try to find available protein structure where there is a significant similarity in the stem
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of the loop27,28.
Often observed errors in homologymodels can be roughly divided into five classes29.
Errors in side-chain prediction, alignment errors, errors in the regions without a tem-
plate, errors due to misalignments and finally the use of incorrect templates. There
are many available programs and webservers developed to assist in the evaluation of
homology models. PROCHECK30 and WHATIF31 check for correct stereochemistry
and structural packing quality of the models and VERIFY3D32 analyzes the compati-
bility of an atomic model with its own amino acid sequence. While programs such as
ANOLEA33 checks for fitness of the sequence to the structure and evaluate the non-
local environment of each of the heavy atom in the molecule. It is often necessary
to go back to the template selection step or the template-target alignment to improve
the quality of the resulting model. Building a number of different models and then
selecting the best one is also advisable.
3.1.2 Docking
Docking methods are use to identify possible drugs against a given protein target.
In general there are two aims of docking studies34. The first is to identify novel lig-
ands by virtual screening (docking), this also includes finding possible poses within
the protein binding site, and the second is to predict the binding affinities of the sug-
gested binding modes (scoring). The binding affinity calculations will be addressed
in the next chapter, but here we will look at how different ligand poses are generated
with virtual screening methods.
All docking programs aim to find the best fit of a ligand to the binding site of the
protein, and they can roughly be divided into three categories depending on which
approach they use for this purpose35. These are systematic methods, random or
stochastic methods and simulation methods. Table 3.1 shows an example of dock-
ing programs that utilize each of this method36.
Systematic search methods
If the systematic search approaches would explore all the possible degrees of freedom
for a given molecule the number of possible combinations would very quickly grow
so large that it would result in combinatorial explosion46. To avoid this systematic
search methods normally use stepwise or incremental searches, for example dividing
the ligands into rigid (core) fragments that are docked first into the active site and
12
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Table 3.1: Common docking programs that utilize systematic, random or simulation methods
in their search for optimal ligand pose, adapted from36
Systematic Random Simulation
DOCK37 AutoDock38 DOCK
FlexX39 MOE-Dock40 Glide
Glide41 GOLD42 MOE-Dock
Hammerhead43 PRO_LEADS44 AutoDock
FLOG45 Hammerhead
flexible parts (side-chains) which are added in incremental fashion39,47 as used in the
program DOCK37. The docking program Glide was used in this thesis and will be
described in more detail here.
Glide is a novel docking program that approximates a complete systematic search
approach, the algorithm is shown in figure 3.241.
Figure 3.2: The Glide docking approach. From41
Each ligand is separated into a core region, which is represented by a number of
conformations, and a number of rotamer groups, which are attached to the core by
13
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a rotatable bond. The core and in addition all of the possible rotamer group confor-
mations is then docked as a single object, which can contain thousands of molecules.
Then an initial screen of possible ligand positions over the active site of the protein
is performed. The positions of ligands are then scored with respect to orientations of
the ligand, steric clashes and hydrogen bonds with so-called "greedy-scoring". The
top scoring poses are refined and re-scored and the best scoring of those are energy
minimized using a molecular mechanics scoring function and the best scoring ones
finally scored using a specialized scoring function as shown in figure 3.241.
Random search methods
In random search, or stochastic methods the ligand is generally considered as a whole
and a ligand pose is evaluated by a pre-defined probability function36. Examples of
random approach algorithms are Monte Carlo, genetic algorithms and Tabu search.
The Monte Carlo algorithm in its simplest form generates a random configuration of
a ligand that is scored, then a new conformation is generated which is scored as well.
The Metropolis algorithm is then used to determine whether the new conformation
is accepted or not. This procedure is repeated until enough conformations are ob-
tained38. Genetic algorithms model conformations of ligands as "chromosomes" that
are stochastically varied and evaluated by a fitness function. The chromosomes that
correspond to the best intermediate solutions are subjected to "crossover and muta-
tion" operations to produce the next generation42. Tabu search on the other hand
takes the conformational space already explored into consideration44,48. In order to
determine whether a given configuration is accepted or not the root mean square
deviation between that conformation and all others is calculated44.
Simulation methods
In the simulation methods the ligand explores the conformational space while the
protein is kept rigid. The conformations that have the lowest energies are then picked
as potential poses. These methods have the limitation of often being unable to cross
high-energy barriers and therefore being bound to a local minimum on the energy
surface35. Number of different ways to circumvent this problem have been sug-
gested, for example to simulate different parts of the protein-ligand system at differ-
ent temperatures49 or to start molecular dynamics calculations from different ligand
positions as implemented in the approach by Pak et al50.
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Receptor flexibility
It is not entirely accurate to view the protein target as completely rigid, which is
the approximation of many docking algorithms. Proteins are frequently observed to
adapt to ligand binding and the importance of that should not be neglected. Var-
ious approaches have been developed to treat protein flexibility, but it’s treatment
is not as advanced as ligand flexibility. These methods include molecular dynamics
and Monte Carlo calculations51,52, use of rotamer libraries53,54 and protein ensem-
ble grids55. Including the receptor flexibility is computationally intensive so those
methods are mostly limited to side-chain flexibility of the binding pocket.
3.2 Molecular Recognition and Binding Affinities
The mutual molecular recognition of proteins with their ligands is the beginning of
most of biological processes. Therefore one of the main objectives of structure-based
drug design is to be able to reliably and accurately predict the binding affinity of
compounds that bind to the target protein. The "lock-and-key" analogy to substrates
binding to enzymes like a key fits into a lock was first introduced by Emil Fischer in
189456. Although this is still a valid analogy since a certain shape complementarity
has to be present between the substrate and the protein, it is also clear that there are
many other factors that play a part in the ligand binding process. In this work we
will only focus on non-covalent binding, which can be viewed as the association of
Protein (P) with Ligand (L) to form a Protein-Ligand complex (PL). Figure 3.3 shows a
schematic picture of non-covalent ligand binding to a protein, and some of the factors
that contribute to protein-ligand binding.
It has been suggested that the electrostatic interactions mainly determines molec-
ular recognition and noncovalent binding57, but this is by no means a general rule.
There are equal evidence to the importance of shape complementarity58. Molecular
recognition can be therefore attributed to contributions of electrostatic and van der
Waals interactions, solvation/desolvation and flexibility of ligand and protein. These
major contributors to molecular recognition are described briefly below
Noncovalent Interactions
Noncovalent interactions are a number of relatively weak chemical interactions that
stabilize the conformations and the interactions between molecules.
Hydrogen bonds result from electrostatic attraction between an electronegative
15
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Figure 3.3: A schematic overview of the main factors of protein-ligand binding and how to
derive binding energies from them. KA is the association constant, and KD, Ki the dissociation
and inhibition constants. ∆G is the Gibb’s free energy. The plots show the kinetic curves used
to extract the values for KD and Bmax
atom and hydrogen that is connected to an electronegative atom, which is usually
oxygen or nitrogen and less frequently fluorine, or from a pi-pi-interactions, or stack-
ing. This also implies that it is very important for theoretical calculations to have
the protonation states of arginine, lysine, aspartic and glutamic acids, as well as his-
tidine correctly determined for an accurate description of electrostatic interactions.
Distances of hydrogen bonds are normally 2.5-3.2 Å and angles of 130◦ -180◦ are typ-
ically found59. The strength of a hydrogen bond depends on its directionality and its
surroundings. The hydrogen bonds in the interior of proteins are stronger than the
ones in the solvent-exposed regions60. In addition ionic bonds are very important
to ligand-protein binding, but their strength is considerably reduced in water due to
shielding.
Water plays an important role in the hydrophobic forces, by forcing hydrophobic
groups together it abolishes disruptive effects on the hydrogen bonded network in
water, which is also known as the hydrophobic effect.
The van der Waals interactions, or London dispersion forces are used to model the
16
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attractive and repulsive forces between molecules. If two atoms are too close to each
other they will repel each other, which makes it possible to define a fixed radius for
the "size" of each atom (van der Waals radius). The contact distance between two
atoms is then the sum of their van der Waals radii. Van der Waals interactions can be
very important when two surfaces of molecules fit well together.
Solvation and Desolvation
Water plays an important role in the formation of protein-ligand complexes. Before
a protein-ligand complex is formed, the individual partners that are not a part of hy-
drophobic surface are involved in hydrogen bonds with the surrounding water. Once
the complex is formed, these hydrogen bonds are replaced with hydrogen bonds be-
tween the ligand and the protein. The contribution of hydrophobic interactions to
protein-ligand binding is normally regarded to be proportional to the size of the hy-
drophobic surface buried during complex formation61,62. Hydrophobic interactions
are also regarded to be the main driving force of conformational change of the recep-
tor upon ligand binding57.
Entropy
The change in the degrees of freedom of the ligand and protein upon binding results
in a change of the entropy63. It can be viewed as the ligand and protein both los-
ing three degrees of translational and rotational freedom, while six new vibrational
degrees of freedom are created for the complex64
3.2.1 Experimental approaches
The ability of theoretical methods to predict the binding affinity of protein-ligand
interactions can be evaluated on how well they are able to reproduce experimental
data.
The general equation for binding association is shown in figure 3.3. If the free con-
centration of the ligand [L] reaches the value of KD, the receptor binding sites are half
saturated with ligand. The value of KD is also half of the Bmax or the maximal specific
binding. In the same way the IC50 concentration is the free ligand concentration at
50% receptor saturation.
The KD and Bmax can be determined with a saturation assay, where different con-
centrations of labeled ligands are added to the assay. The data is normally analyzed
by Scatchard analysis where the amount of bound ligand divided by the amount of
free ligand is plotted against the amount of bound ligand. The slope is then the KD
17
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and the x-axis intercept is the Bmax. More recently this method is being replaced by a
non-linear regression analysis.
The IC50 concentration is determined with a competition assay to a labeled ligand.
This has the advantage that each of the ligands that is being tested does not have to
be explicitly labeled but rather tested against an already labeled molecule. The Ki
constant is then determined from the Cheng-Prusoff equation65
Numerous binding assays have been designed to experimentally determine bind-
ing affinities, these can be divided into methods that require separation of the com-
ponents or do not require separation of the components for analysis.
Separation Assays
In separation assays the target protein is incubated with a labeled ligand (radioactive
or fluorescence) until equilibrium is reached. The amount of bound ligand is esti-
mated after separating the unbound ligand from the bound normally by centrifuga-
tion or filtration. These assays can either be saturation assays or competition assays,
an example of a separation assay is the radioligand-binding assay which has been
used very successfully for the high throughput drug discovery process66
Direct Assays
In direct assays the protein-ligand interaction is measured in real-time. This is conve-
nient because it does not require separation of the components prior to measurement.
One method commonly used is fluorescence polarization which measures the change
in polarization of light emitted from a fluorescent labeled ligand from when it is ro-
tating freely to when it is bound to a protein target. The light emitted from the freely
rotating ligand is depolarized due to the rapid motion of the ligand, whereas the ro-
tational speed decreases when it is bound to a high-molecular weight protein target
and the emitted light stays polarized. This method has also been successfully used in
high throughput drug discovery and has the advantage over radioligand assays that
it is non-radioactive and considerably cheaper67.
3.2.2 Computational approaches
There is a need for fast, accurate and reliable methods to calculate the binding affinity
of ligands to proteins68. These methods should ideally help the drug discovery pro-
cess by enabling the pre-screening of potential drugs and as a consequence reduce
the number of compounds that need to be screened by in vitro/vivo experimental
methods. The available computational methods differ considerably in their accuracy
18
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and complexity. Affinity calculations in the docking context have to be able to deal
with a very large number of compounds in a relatively short time. These methods
therefore tend to only deal with a single structure of the docked pose and focus on
a fast calculation, making numerous approximations to obtain a reasonable ranking
of compounds, rather than accurately calculate absolute binding affinities. On the
other hand simulation methods use techniques such as Monte Carlo or Molecular
Dynamics to obtain conformational sampling for increased accuracy, which in turn
makes them more computationally intensive and therefore not easily applicable to
high-throughput virtual screening.
The sections below describe briefly a number of methods that are commonly used
to calculate binding affinities between protein and ligands. They are divided in
whether they are methods that aim to calculate binding affinities from one structure
such as a docked pose from a virtual screening or usingmolecular dynamics orMonte
Carlo sampling to calculate the binding affinities from an ensemble of structures.
Single Structure from Docked Poses
The scoring functions that are used in virtual screening have to be able to deal with
large number of compounds in short time. It is important to have a scoring function
that is able to correctly rank the poses generated and thereby dismiss the poses that
are incorrect. The most commonly used scoring functions used in virtual screening
can be divided into knowledge-based, empirical and force-field based methods. Each
one of those methods has its approximations and limitation so often the results can
be improved by combining various scoring functions69.
Knowledge-based scoring
In knowledge-based scoring the focus is more towards reproducing the actual struc-
tures instead of the energies. They are based on atomic interaction-pair potentials
which are derived from observations of contacts from known ligand-protein com-
plexes available in databases such as the PDB10 and Cambridge Structural Database
(CSD)70. Scoring functions that use this method are for example potential of mean
force (PMF)71 and DrugScore72. These methods tend to be simple to compute ef-
ficiently, but a drawback is that the number of available protein-ligand complexes
needed to derive the parameters is limited36.
Empirical scoring
The empirical scoring scheme uses combination of several parameters that are then
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fitted to reproduce experimental energies73. The parameters are selected to best cover
all the important contributions of the total binding free energy, such as hydrogen
bonds, hydrophobic and ionic interactions, and an entropic term to account for the
loss of conformational freedom. The coefficient of the parameters used to fit the data
are obtained using regression analysis from experimental binding free energies and x-
ray structure information as atomic interaction-pair potentials36. Examples of scoring
functions that use this method are LUDI73 and ChemScore74. An advantage of this
scoring function is that it has a simple functional form but it is dependent on data
sets for fitting resulting in different weighting factors36.
Force-field based scoring
Force field based scoring functions avoid specific parameterization by using well es-
tablished molecular mechanics force fields to estimate the binding energy of non-
bonded interactions (vdw, hydrogen bond and electrostatics)36. An example of force
field based scoring functions are G-Score75 andAudoDock76. These scoring functions
are generally limited by the exclusion of solvent and entropic terms, although recent
implementation include an entropy term and solvation energy using PBSA or GBSA
models77.
Molecular Mechanics Methods
Estimating binding free energies accurately is a very time-consuming process. The
most accurate results are obtained with methods such as Free Energy Perturbation
(FEP) / Thermodynamics Integration (TI), and similar results can be obtained at a
lower computational cost with methods such as MM-PBSA/MM-GBSA or Linear In-
teraction Energy (LIE). These methods are however still considered too computation-
ally intensive to be of much use in virtual screening approaches.
Free Energy Pathway methods
FEP and TI methods are often referred to as "computational alchemy", in the sense
that they evaluate the difference between the binding energy of two similar ligands
by using pathways to compute the change in free energy when ligand A is changed
to ligand B within the binding site and in solution78. These methods generally give
a very good estimate of the binding energy, with errors below 1kcal/mol79,80. By
slowly "growing" the ligand into the binding site it is also possible to calculate the
absolute binding free energy, but this is a very time consuming process81.
Figure 3.4 shows the thermodynamic cycle that is used for chemical alchemy cal-
culations.
20
3.2 Molecular Recognition and Binding Affinities
L
PL
PL
∆Gbind(L1)
∆Gbind(L2)
L1 1
2 2
∆∆GL
mut
∆∆G PL
mut
P
P +
+
Figure 3.4: The thermodynamic cycle used for TI calculations, adapted from82. P is the protein
and L is the ligand, PL is the protein-ligand complex.
By using this thermodynamics cycle the difference binding free energy between
ligand1 and ligand2 can be calculated as:
∆∆Gbind = ∆Gbind(L1)− ∆Gbind(L2)
= ∆∆GmutPL − ∆∆GmutL
(3.1)
MM-PBSA and MM-GBSA
MM-PBSA and MM-GBSA are so called end-point methods in the sense that they
only evaluate the initial and final states of the system instead of the path between the
states. They can use molecular dynamics or Monte Carlo simulations to obtain snap-
shots of the protein-ligand complex which are used to calculate the average binding
free energy. If the configurational entropy is included it is estimated by minimiz-
ing a small number of snapshots and from them calculate the entropy with a rigid-
rotor/harmonic-oscillator approximation68, but often this term is neglected if only
relative binding affinities are required because it is very time consuming.
Figure 3.5 shows the thermodynamics cycle used inMM-PBSA/GBSA calculations.
The binding free energy is decomposed into contributions from the gas phase and
solvation free energy that arises from the gas phase to water transition:
∆Gbind = ∆GPL − (∆GP + ∆GL) (3.2)
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Figure 3.5: The thermodynamic cycle used for MM-PBSA/GBSA calculations
where
G = Ggas + Gsolv = (Hgas − TS) + Gsolv (3.3)
The solvation contribution Gsolv can be decomposed into contributions from elec-
trostatics and nonpolar interactions.
Gsolv = Gelec + Gnonpolar (3.4)
The nonpolar contribution is assumed to be proportional to the solvent accessible
surface area (SASA). The electrostatics contribution is solved using an implicit solvent
model either PBSA83 or GBSA84. The enthalpic contributions are calculated using a
force field approximation:
Hgas ≈ Egas = Ebond + Eangle + Etorsion + Eelec (3.5)
The energies are normally averaged over conformations sampled from molecular
dynamics simulations, often with explicit water. These methods have been applied
to a variety of ligand-protein complexes and proven to give good estimates of the
binding energy85.
Linear Interaction Energy
The Linear Interaction Energy (LIE)methods86 are end-pointmethod likeMM-PBSA/GBSA
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and also use averaged conformations from molecular dynamics simulations. The
binding free energy is estimated as:
∆Gbind ≈ α(< Eelec >bound − < Eelec >free) + β(< Evdw >bound − < Evdw >free)
(3.6)
where the brackets denote averages from molecular dynamics trajectory. The fac-
tors α and β account for changes in the internal energy of the solvent and protein and
are determined empirically86. This method has been shown to give accurate results86
and newer implementation include a solvation energy term to increase accuracy87.
A drawback of this method is that there is no universal value for the factors α and
β, they have to be determined independently for each case and require experimental
data.
3.3 Protein Dynamics
Molecular dynamics simulations are commonly used to get information on time evo-
lution of conformations of biological macromolecules such as proteins. They provide
information on motions of individual atoms as a function of time and thereby en-
able us to better understand the properties of molecules and the interactions between
them. The first molecular dynamics simulations was performed in 1957 using a so
called hard sphere model88. In 1964 Rahman improved this rough model by apply-
ing a smooth, continuous potential which better mimics the atomic interactions89.
With increasing computer power the possibility of molecular dynamics simulations
has also steadily increased and since 1976 when the first MD simulation of a protein
was performed90 the use of MD simulations has steadily increased and today molec-
ular dynamics simulations are widely and commonly used in physical and biological
sciences.
The interaction within a protein or between a protein and a ligand is normally
described by a force field, such as the CHARMM force field91. It contains several
discrete terms, which describe the intermolecular and intramolecular forces in the
system:
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U ~(R) = ∑
bonds
Kb(b− b0)2 + ∑
Urey−Bradley
KUB(S− S0)2 + ∑
angle
Kθ(θ − θ0)2+
∑
dihedrals
Kχ(1+ cos(nχ− δ) + ∑
impropers
Kϕ(ϕ− ϕ0)2+
∑
nonbond
eij[(
Rminij
rij
)12 − (
Rminij
rij
)6] +
qiqj
erij
(3.7)
where for the bonded interactions Kb, KUB, Kθ, Kχ, and Kφ are the constants for
bond length, Urey-Bradley (1-3 bond length), bond angle, dihedral angle, and im-
proper dihedral angle force, respectively. In the same way d, S, θ, χ and φ refer to
the bond length, Urey-Bradley (1-3 bond length), bond angle, dihedral angle and im-
proper dihedral angle values, the zero refers to the equilibrium values. For the non-
bonded interactions, eij refers to the Lennard-Jones well depth, Rminij to the distance
at which the interparticle potential is zero, qi is the partial atominc charge of atom i,
e is the effective dielectric constant, and rij is the distance between atoms i and j.
The CHARMM force field contains a set of parameters for the standard 20 amino
acids, nucleic acids and a number of organic molecules91. These parameters make
it possible to simulate proteins and any system that is described within these pa-
rameters91 . However, if the intention is to simulate molecules that are not described
within this set as is often the case in drug discovery processes, the relevant parameters
need to be obtained92. Manually determining parameters is very time-consuming
task and not well adapted for a large-scale simulation of protein-ligand complexes.
Fortunately, there exist a number of programs to assist with parameterization such as
Wit!P (A.Widmer, Novartis) and Antechamber93.
The energy landscape of proteins has often been described as containing one global
minimum and a number of local minima. These minima are separated by energy bar-
riers which the protein must cross in order to adapt to a new conformation. In this
sense the shape and roughness of the landscape determine the dynamics behaviors of
the protein. It has been suggested that the potential energy surface that describes the
native state of proteins contains multiple minima that correspond to very similar con-
formations94. This observation was confirmed by molecular dynamics simulation95
and later experimentally96. Molecular dynamics studies must therefore be able to
explore states of interest. In contrast, to protein folding/unfolding where exhaus-
tive sampling of the entire energy landscape is necessary, in the work presented here
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it is sufficient to sample the protein-ligand binding ensamples to obtain a realistic
sampling. There are numerous molecular dynamics methods that have been devel-
oped to efficiently explore the energy surface of interest. Among these are methods
that modify the energy landscape such as metadynamics97 or stochastic tunneling98,
methods that increase the temperature to attempt to overcome barriers, such as sim-
ulated annealing99 or multiple simulations. In addition, increased computer power
which often uses parallel environment makes it possible to perform molecular dy-
namics simulations that extend into the microsecond timescale100.
3.3.1 Multiple Molecular Dynamics Simulations
An alternative way to enhance the conformational sampling is to perform multiple
short molecular dynamics simulations, instead of a single long one101,102. In other
words, instead of running one simulations using many CPUs the simulation is split
up into multiple, independent simulations that are calculated on separate computers.
These independent simulations can then later be combined and analyzed as a com-
plete set. The length of the short molecular dynamics simulations limits the processes
that can be observed. Therefore it is important to have knowledge of the system to
choose suitable time scales. Table 3.2 lists time scales and movements commonly
observed in proteins.
Table 3.2: Timescales and motions commonly observed in proteins
Time scale Amplitide Description
femto to pico 0.001 - 0.1 Å bond stretching, angle bending
constraint dihedral motion
pico to nano 0.1 - 10 Å unhindered surface side chain motion
loop motion, collective motion
nano to micro 1 - 100 Å folding in small peptides
helix coil transition
micro to second 10 - 100 Å protein folding
There have been numerous attempts of running multiple short trajectories and
comparing the results to those obtained from a single long one. Auffinger et al looked
at the hydration of tRNA(Asp) anticodon by running six 500 ps multiple molecular
dynamics trajectories. They found that even if the trajectories were similar in dy-
namical characteristics they displayed different local hydration patters which reflects
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the conformational landscape that is explored103. Caves et al looked at the differ-
ences in sampling between running an individual trajectory of 5ns or ten indepen-
dent trajectories of 120 ps each, which only differ in the initial velocities. They found
that the overall sampling was improved by using the multiple independent trajec-
tory approach and suggest that this should be used to obtained better sampling104.
Loccisano et al looked at the A1− > A1,3 transition in MbCO. They found that by
running ten 400 ps simulations they were able to observe this transition frequently,
while using two 1.2 ns simulations they were only able to observe it once. The initial
structures came from five x-ray structures with random initial velocities105. Other
attempts have shown improved sampling by running multiple molecular dynam-
ics simulations, time scales ranging from 100 ps to few nanoseconds and the num-
ber of short simulations from being less than 10 to around 1000. These simulations
vary from studying the conformational space of small peptides and proteins106,107 to
studying ion channels and lipid bilayer108,109.
Until now not much has been done to investigate multiple short trajectory ap-
proaches in the context of improving conformational sampling for protein-ligand in-
teractions. Brown et al showed that they could obtain comparable correlation to ex-
perimental binding free energies of biotin to avidin by running six 13ps short molec-
ular dynamics simulations on a Grid.110. They extended this approach to show that
they could obtain reasonable correlation to experimental data for 18 ligands of uroki-
nase111. In both cases there is only one short trajectory for each of the minimized
structures and the analysis only consists on monitoring the RMSD and correlation to
experimental values.
3.4 Protein Systems Studied
In order to be able to further our understanding of molecular recognition and to de-
velop algorithms that improve scoring functions, it is necessary to have well estab-
lished protein systems available for study. In this work we use two protein systems,
the HIV-1 protease and the Estrogen Receptor β, both of which have numerous struc-
tures available in the protein data bank and a large number of known ligands that
bind to them.
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3.4.1 HIV-1 Protease
TheHIV-1 protease is an aspartic protease that has a crucial role in the viral replication
cycle of the HIV-1 virus, where it cleaves newly synthesized polyproteins to produce
mature components of infectious HIV-1 virions. Studies have shown that if the HIV-
1 protease is unable to perform its duties the resulting virions are not infectious112.
This makes the HIV-1 protease an ideal target for drug discovery and currently there
are four inhibitors of the HIV-1 protease in clinical use and more that are undergoing
clinical trials113,114.
Several high-resolution x-ray structures have been determined to date, with ≈ 350
structures available in the PDB. Figure 3.6 show the structure of the HIV-1 protease
(A) and a schematic view of the binding site residues.
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Figure 3.6: The HIV-1 protease (A) and a schematic view of the binding site residues (B)
The protease is a homodimer consisting of 99 residues each. The active-site residues
(Asp25-Thr26-Gly27) are located in a loop which is stabilized by a network of hydro-
gen bonds. The carboxylate groups of Asp25 from both chains are nearly coplanar
and show close contacts. The network is quite rigid due to the interaction (called
"fireman’s grip") in which each Thr26 OG1 accepts a hydrogen bond from the Thr26
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main-chain NH of the opposing loop. Thr26 also donates a hydrogen bond to the
carbonyl O atom of residue 24 on the opposite loop114. The HIV-1 protease contains
two flaps which cover the active site and participate in the binding of their natural
substrates and inhibitors. A common feature to most complexes of HIV-1 protease
is a water molecule that is separated from the bulk solvent and bridges the inhibitor
and Ile50 and Ile150 NH groups of the flaps114.
Most of the HIV-1 protease inhibitors that are being designed are inhibitors that
compete with the natural substrate for the same active site115. An alternative ap-
proach has been suggested with ligands that bind at the subunit interface and thereby
destabilize the dimeric structure, but so far these efforts have not been very success-
ful116.
3.4.2 Estrogen Receptor beta
The Estrogen Receptor belongs to the nuclear receptor family of transcription fac-
tors (NR). It functions as a ligand-regulated transcription factor by binding to cis-
regulatory DNA elements in the promoter117.
Estrogen receptors control many physiological processes that can be influenced by
agonist or antagonist ligands. Estrogen agonists are for example used in the treatment
of postmenopausal osteoporosis118, atherosclerosis119 and Alzheimer’s disease120.
However, the activation of ER can also increase the risk of breast and uterine can-
cer121,122. Drug discovery efforts concerning the ER α have already resulted in suc-
cessful drugs that are currently used in therapy123,124.
A second ER subtype or ER β was recently discovered and isolated in 1996125. Its
discovery caused some excitement in the drug discovery field due to the successes in
developing drugs against ER α. The tissue distribution differs considerably126 and so
does their biological function127,128. Figure 3.7 shows the structure of ER β (A) and
the sequence similarity of the two ERs (B).
The two ER receptors share 95% sequence identity in their DNA binding domain,
but only≈ 57% identity in their ligand binding domain (LBD)129. The binding pocket
itself is however very similar, only two amino acid difference, L384 and M421 in ER
α are M336 and L373 in ER β respectively.
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Figure 3.7: The Estrogen Receptor β (A) and its sequence identity to ER α (B)
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This chapter describes the theoretical methods used in this work. Figure 4.1 shows
the methodological organization of the work.
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Figure 4.1: A flowchart describing the workflow used in this thesis. The gray squares refer
to the common aspects of all the projects, and the white squares refer to the parts that vary
between different approaches.
The general workflow for the molecular dynamics simulations is always the same.
The input structure (protein and ligands) has to be parameterized before a molecu-
lar dynamics simulation is performed. After the molecular dynamics simulation has
completed an analysis is performed. The input structures can come from structures
that have been solved experimentally (x-ray) or by homology modeling and the lig-
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ands are either the natural ligands or poses obtained from docking. These structures
have to be parameterized and are done so either by manual or automatic means. The
molecular dynamics simulations are either run as a single long simulation or multi-
ple short ones. Finally, the type of analysis that is performed varies according to the
problem that is being addressed.
4.1 Parameterization
The ligands used in this work are not a part of the standard CHARMM parameter
set91. As a consequence their specific force field parameters have to be determined,
either manually or by an automated procedure.
Manual parameterization
The manual parameterization was done by analogy to known parameters. The atoms
of the ligand were compared to similar atoms of known types already existing in the
force field and values for partial charges, similar bond, angle and dihedral values
were used.
Automatic parameterization
The software package Antechamber was used for the automatic parameterization of
partial charges and force field parameters93. The workflow is as following; a pdb file
of the ligand to be parameterized first has to be renumbered so that the atom num-
bers are corresponding to AMBER. Then the Mulliken partial charges are calculated
from basic laws of quantum mechanics using the electronic structure program Gaus-
sian130. Antechamber is then used to produce the necessary residue topology file and
parameter file. The atom type naming is different in AMBER than in CHARMM so all
of the atom types of each ligand were renamed and the corresponding files checked
for errors and missing parameters.
4.2 Input Structures
All of the work in this thesis is based on structures where three-dimensional coor-
dinates are available. Either the protein structures have been solved experimentally
by x-ray crystallography or they are modeled using homology modeling. For the
ligands, either they come from known x-ray structures or they come from docking
algorithms.
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X-ray structures
The experimentally determined structures used for the HIV-1 protease and it’s lig-
ands are the same as used in a previous study131 with pdb access codes 1HVL, 1HVK,
1HVI, 1HVJ, 1DIF, 1OHR, 1AJX, 1AJV, 1HTF, 1HPX, 1HSG, 2BPV, 1HBV, 1HOS, 1HPS
and 1HPV. For the Estrogen Receptor the structures were selected from the pdbbind
database based on their experimentally determined binding affinities132, pdb access
codes 2BJ4, 1B1V, 1X7E, 2FAI, 1GWR, 1GWQ, 1XQC, 1UOM, 1XPC, 1XP9, 1SJ0, 1XP1
and 1XP6. All the coordinates of the protein structures were then obtained from the
Protein Data Bank (PDB)10
Homology Models
The homology models for the HIV-1 protease were based on templates from the
Simian Immunodeficiency Virus (1SIP, 51% sequence identity)133, HIV-2 protease (1IDA,
48% sequence identity)134, Rous sarcoma virus (1BAI, 40% sequence identiy)135, Equine
infectious anemia virus protease (1FMB, 32% sequence identity)136 and Feline im-
munodeficiency virus (3FIV, 32% sequence identity)137. The homology models were
built using the comparative modeling server SWISS-MODEL19. The project submis-
sion mode20 was used and all models were validated using Procheck30 to assess the
stereochemical quality of the models and Anolea mean force potential assessment33
to evaluate the environment of heavy atoms.
Docked ligands
First the ligands are prepared for docking using the LigPrep module of Maestro in
the Schrodinger suite of software afterwards the bond order of the ligands have to be
manually corrected. The protein structure 1HVI was used for the HIV-1 protease as
the reference structure in which all the ligands were docked, and the structure 1XPC
for the Estrogen receptor. The protein preparation workflow was used to correctly
set up the protein by assigning bond order, add hydrogens, generate ionization states
and minimize the protein structure. A docking grid was set up with the receptor grid
generation tool and the docking was performed with Glide v4.541. For the ligands
of HIV-1 protease two docking runs were performed, one for the ligands that con-
tain a structural water in the binding pocked and a separate run for the two ligands
(AHA001 and AHA006) that do not contain the structural water. The aspartic acid 25
of chain 1, or Asp25 was protonated on OD1.
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4.3 Molecular Dynamics
For both of the standard long and multiple short molecular dynamics simulations,
the first steps of solvating, equilibration and heating are the same as described below.
The molecular dynamics (MD) simulations were performed using CHARMM138
version 30b1 and the all-atom force field CHARMM2291. The starting coordinates for
the MD simulations were the coordinates of the ligands in their experimentally deter-
mined structures, or the structures obtained from docking experiments, respectively.
All protein-ligand complexes were superimposed, and the coordinates of the ligands
were transferred into the chosen reference structures. Partial atomic charges and the
all-hydrogens parameters for van der Waals and bonded energy terms for the ligands
of HIV-1 protease have been previously determined131 and applied to validate the
MM-GBSA approach139. The ligands for the estrogen receptor were automatically
parameterized using Antechamber93.
Each of the protein-ligand complexes was solvated with a water sphere of radius
24 Å, centered on a ligand atom which is in the center of the protein-ligand complex.
The stochastic boundary method was used140, with a reaction region of 20 Å and a
buffer region of 4 Å. Electrostatic interactions were shifted and calculated with a 12
Å cutoff and the van der Waals interactions were switched at long range.
The water molecules were equilibrated at 300 K for 80 ps with the protein and
ligand fixed. Then the complex was minimized for 200 steps of steepest descent min-
imization and then heated and equilibrated from 0 K to the target temperature in
steps of 40ps for each 100K increase. The target temperatures for the validation were
300K and 500K. Harmonic restraints of 5 kcal/mol initially applied to the ligand and
protein atoms within the reaction region were slowly removed during the heating.
At the target temperature all restraints were removed from the reaction region and
equilibration continued for 40ps at constant temperature. Heavy atoms in the buffer
region were coupled to a heat bath, using the Langevin equation of motion and a
250 ps−1 friction constant141. A friction constant of 62 ps−1 was applied to the water
oxygens.
After the heating and equilibrium steps have completed different molecular dy-
namics approaches are applied.
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4.3.1 Standard long MD simulations
For the standard long molecular dynamics simulation, the simulations were were
carried out at the target temperature using Langevin dynamics during 500 ps with a
time step of 1 fs.
4.3.2 Multiple MD simulations
The general methodology for the parallelization of the multiple short molecular dy-
namics simulations is shown in figure 4.2.
Preparation
Presimulation
Coordinate/
velocity 
extraction
Multiple short
simulation
Figure 4.2: An overview of the workflow for the multiple short molecular dynamics simu-
lations approach. First as with standard long molecular dynamics, the protein and ligand
coordinates, along with the necessary force field parameters are used to run a so-called pre-
MD simulation. This pre-simulations is normally run 100ps and every 1ps coordinates and
velocities are extracted. These coordinates and velocities are then recombined and used as
starting points for for multiple short molecular dynamics simulations of 10ps each, which can
be run on a PC GRID
As for a standard long molecular dynamics simulation, the necessary force field
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parameters along with the coordinates of the protein and a number of ligands are
used as an input to run a molecular dynamics pre-simulation. This pre-simulation is
performed for 100ps with coordinates and velocities are extracted every 1ps. These
coordinates and velocities are then recombined and used as starting points for inde-
pendent short MD simulations of 10ps each, totaling in 100 short MD simulations.
As a first attempt the coordinates and velocities are simply combined as coordinate
i with velocity i+1. These short simulations are then suitable for execution on a PC-
GRID, and their total combined simulation time of 1ns is presumed to produce results
comparable to a single continuous MD simulation of 500ps102,104.
4.4 Analysis
4.4.1 Binding Energy Evaluation
Frames from both the long and the short MD simulations were extracted every 1 ps,
resulting in 500 frames for the long simulation and 1000 for the multiple short ones.
The binding free energy ∆Gbind was calculated using the MM-GBSA approach84.
∆Gbind can be decomposed into a sum of the gas phase contribution, ∆Evacuo, the
desolvation energy upon binding, ∆Gdesolv, and an entropy contribution, T∆S:
∆Gbind =< ∆Evacuo > + < ∆Gdesolv > − < T∆S > (4.1)
The brackets indicate ensemble averages of the quantities calculated from the ex-
tracted frames from each of the trajectories. In this approach, the gas phase con-
tribution is equal to the van der Waals (∆Evdw) and electrostatic (∆Eelec) interaction
energies between the ligand and the protein, and the difference of the internal energy,
∆Eintra between the complex and the separated ligand/protein system (deformation
energy). However, since we only use the trajectory of the complex, ∆Eintra = 0 and it
does not enter the subsequent calculations.
The desolvation energy, ∆Gdesolv, is the difference between the solvation energy of
the complex, ∆GCsolv, and of the ligand and protein, ∆G
L
solv and ∆G
P
solv, respectively.
The solvation for all three systems can be further divided into electrostatic (∆Gsolv,elec)
and nonpolar (∆Gsolv,np) contributions. The electrostatic contribution to the solva-
tion free energy (∆Gsolv,elec) was estimated from the analytical Generalized Born (GB)
GB-MV2 model implemented in CHARMM142,143. Calculations using this model are
much faster compared to numerically solving the Poisson equation (as required for
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PBSA calculations83,144) and were found to reproduce solvation energies with 1% ac-
curacy compared to the Poisson model. Recent results show that the deviation in
the desolvation energy between the GB-MV2 model and the PB model is constant,
which means that the use of GB-MV2 does not alter the ranking of the ligands145.
Also, using the GB-MV2 model allows for easier decomposition of the electrostatic
energy than is possible with PBSA. The nonpolar contribution is assumed to be pro-
portional to the solvent accessible surface area (SASA). This approximation is based
on the observation that the solvation of saturated nonpolar hydrocarbons is linearly
related to the SASA146. A value of 0.0072 kcal/mol Å 2 was used for the surface ten-
sion84,147,148. The solvent accessible surface areas were calculated analytically with
CHARMM, with a solvent probe radius of 1.4 Å .
The entropic contribution, T∆S, corresponds to the contributions of translational,
∆Strans, rotational, ∆Srot and vibrational, ∆Svib entropies:
−T∆S = −T∆Svib − T∆Strans − T∆Srot (4.2)
where each of these terms is calculated from standard equations of statistical me-
chanics149,150. The entropic contribution is required for calculating absolute binding
free energies. T∆Strans and T∆Srot are functions of the mass and moments of inertia,
while T∆Svib is calculated from a normal mode analysis150. Since the normal mode
calculations are computationally very demanding, −T∆S was only averaged over 20
frames of the trajectory. The VIBRAN module of CHARMM was used to determine
the normal modes and normal mode frequencies. The normal modes were calculated
in vacuo for a fully minimized structure of the molecule (complex and protein:ligand)
with a distance dependent dielectric, e = 4r. The minimization was performed using
the Adopted Basis Newton-Raphson algorithm, until the root mean square of the en-
ergy gradient reached 10−7 kcal/molÅ. This gradient value is expected to give only
real frequencies150. The minimized structures were also used to calculate the mo-
ments of inertia. Since T∆Svib is computationally very demanding to calculate and
we are only interested in relative energies, the entropic term was calculated for all the
ligands docked in the reference protein 1HVI to verify that a ranking of the ligands
can be obtained without including the entropic term. Thus, the working equation to
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estimate binding free energies is
< ∆Gbind >=< ∆Eelec > + < ∆Evdw > + < ∆Gdesolv,elec > + < ∆Gdesolv,np > .
(4.3)
4.4.2 Correlation to Experimental Values
The correlation of the calculated binding free energies was based on its linear regres-
sion to the experimental binding free energy values.
The correlation coefficient is determined by first calculating the standard deviations
of the x and y datasets:
σ =
√√√√ 1
N
N
∑
i=1
(xi − x)2 (4.4)
The standard deviation is calculated the same way for y. Then the covariance be-
tween the two data sets is determined by:
σx,y =
1
N
N
∑
i=1
(xi − x)2(yi − y)2) (4.5)
Finally the correlation coefficient is defined as:
r =
σx,y
σxσy
(4.6)
4.4.3 Principle Component Analysis
The program Gromacs151 was used to examine the positional differences of the coor-
dinates from different molecular dynamics approaches and simulations at different
temperatures. The gcovar module was used to calculate and diagonalize the covari-
ance matrix and corresponding eigenvectors are determined. The eigenvectors were
analyzed with the ganaeigmodule.
4.4.4 Clustering
We are interested in finding out if the different simulations approaches (standard
long and multiple short) are equivalent. Clustering is a commonly used method of
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grouping together data that are similar in some way, which is determined by a given
criteria or cluster metric. In this work we have used two different cluster metrics.
They both deal with residues that are in the binding pocket, within 5 Å of the ligand
and consider each frame of the molecular dynamics simulation separately. The first
metric is based on a per residue binding free energy decomposition and the second
on a simple root mean square deviation (dRMSD) to a reference structure,
Binding Energy Decomposition
To estimate the contribution of each of the residues of the protein to the total binding
free energy, an energy decomposition of the binding free energy for each residue was
performed.
For the electrostatic interaction energy between the residues of the protein and the
ligand, one half of the energy is attributed to the ligand and the other half to the
protein residue. The contribution of atom i to the total electrostatic interaction energy
is given by:
Eielec =
1
2∑j
qiqj
rij
(4.7)
where j loops over all the atoms of the component to which i does not belong, i.e.
over the protein if i belongs to the ligand, or over the ligand if i belongs to the protein.
rij is the distance between atoms i and j and qi and qj are their atomic charges. For
the pairwise van der Waals interactions between the protein and ligand, one half is
attributed to each atom involved in the interaction.
The solvent accessible surface area of atom i in the complex, SASAi,C, and in the
protein, SASAi,P, and ligand, SASAi,L, is calculated by CHARMM. The contribu-
tion of atom i to the nonpolar desolvation term is thus ∆Ginp,solv = σ(SASA
i,C −
(SASAi,P + SASAi,L)). The electrostatic solvation term is calculated using the GB-
MV2 approach, which uses the Still et al.147 expression for the electrostatic solvation
term:
∆Gelec,solv = k∑
i,j
qiqj√
r2ij + αiαjexp(−r2ij/Ksαiαj)
(4.8)
where k = −166.0(e−1solute − e−1solvent). esolute and esolvent are the dielectric constant,
i.e. 1 and 80, respectively and αi and αj are the Born radii of atoms i and j, calculated
with the GB-MV2 approach. i and j loop over all atoms of the system. The constant
Ks is equal to 8 in the GB-MV2 approach. The contribution of atom i to ∆GXelec,solv can
39
4 Methods
therefore be written as:
∆Gi,Xelec,solv = k
q2i
αi
+
1
2
k∑
j 6=i
qiqj√
r2ij + αiαjexp(−r2ij/Ksαiαj)
(4.9)
where X stands for the complex, the protein or the ligand. The contribution of atom
i to the electrostatic desolvation energy is ∆Gielec,desolv = ∆G
i,C
elec,solv − (∆Gi,Pelec,solv +
∆Gi,Lelec,solv). Adding all these atomic contributions over the atoms of a given residue
or side chain or backbone fragment yields its contribution to the total binding free
energy.
This binding free energy is calculated for those residues that fall within 5 Å of the
ligand for all frames of the molecular dynamics simulations that are being compared.
Distance RMSD
For calculating RMSD as distancemetric, only atoms of the side-chains of the residues
that fall within 5 Å of the ligand are considered. First for the reference structure (x-ray
structure), all the pairwise distances between each each residue atom to each ligand
atom are calculated by:
Dresdistance,ref(Γ
ref) =
√
1
Npair
∑
i,j
(rresi − rligj )2, (4.10)
where Γref correspond to the reference structure. Npair the total number of distances
compared, that is all the interacting pairs and rresi - r
lig
j is the distance between atoms
i of the protein residue and atoms j of the ligand.
The Dresdistance,ref is calculated for all of the residues of the reference structure and
then for all residues of all frames for themolecular dynamics simulations (Dresdistance,frame
). The difference in distance for each the residue for each the frames during themolec-
ular dynamics simulation can then be defined as:
∆Dres(ref−frame) = |Dresdistance,ref − Dresdistance,frame| (4.11)
In the same way as with the binding free energy criteria, the ∆Dres(ref−frame) values
are given an integer score depending on which distance interval they belong to.
Scoring
Once the different clustering metrics have been defined and calculated, the corre-
sponding results from the molecular dynamics simulations can be compared and
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clustered. The analysis workflow is depicted in figure 4.3.
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Figure 4.3: An overview of the fingerprint definition scheme. The first step identifies all
residues that fall within a certain radius of the ligand (1). In the second step the maximum
and minimum values for the criteria of choice are defined and the values are split into even
intervals (2). In the third step a fingerprint is created for each of the frame under investigation
(4). The fingerprints are then scored all-to-all (4) and clustered as described in the text (5-7)
The first part of figure 4.3 (1), or the definition of a clustering metric and calculation
of values has already been discussed. The following sections describe the fingerprint
definition figure 4.3 (2 and 3), scoring of the results figure 4.3 (4) and the affinity prop-
agation algorithm to cluster the data 4.3 (5-6).
Fingerprint Definition
As described above, for each of the residues of the protein that falls within 5 Å of the
ligand a binding free energy and distance metric is calculated for all frames consid-
ered. In order to simplify the fingerprint definition the resulting continuous values
from the rmsd or binding free energy metric are assigned an integer score depend-
ing on which interval the fall into. For the binding free energy metric the intervals
are divided for each 1kcal/mol energy contributions up to ± 8 kca/mol. In this way
residues that have an energy contribution of 0.5 kca/mol in one frame get the score 1
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(the interval from 0-1 kcal/mol), whereas if in the next frame the energy contribution
is 1.6 kcal/mol it would get the score 2 (the interval from 1-2 kcal/mol), until ± 8
kca/mol all contributions over +8 kcal/mol get the same score and in the same way
the contributions that are less than -8 kcal/mol.
The fingerprint for the distance metric is defined in a similar way, by dividing the
dRMSD value of each residue to the ligand for each frame of the trajectory to the same
distance in the reference structure into intervals of 0.5 Å up to the distance difference
of ± 3 Å
Once these scores have been defined the fingerprints can be produced as shown
in figure 4.3 (3). Each of the columns refers to a residue and each of the lines corre-
sponds to a single frame of a molecular dynamics simulation. For each of the metrics
a fingerprint represents a profile of the interactions of residues to the ligand for the
molecular dynamics simulation frame under consideration.
The fingerprints between frames of a molecular dynamics simulations can now be
compared pairwise and given a score depending on how distant they are from each
other (Hamming score) as described below.
Hamming scoring
The Hamming scoring function is defined as followed:
DAB =
m
∑
i=0
| Ai − Bi | (4.12)
where DAB is the distance score between fingerprint A and B and | Ai − Bi | is the
absolute difference between the values of column i of fingerprint A and B.
The calculation by this scoring functions results in a list of pairwise comparisons
as depicted in figure 4.3 (4).
Clustering
Once the fingerprints have been defined and have been scored according to the Ham-
ming or Tanimoto score, they can be clustered based on their similarity. In this work
we use the affinity propagation clustering.
Affinity Propagation
The affinity propagation algorithm152 identifies exemplars among data points and
forms clusters of data points around these exemplars. It operates by simultaneously
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considering all data point as potential exemplars and exchanging messages between
data points until a good set of exemplars and clusters emerges.
4.4.5 Analysis of Clusters
Once a reliable set of clusters has been obtained, it is interesting to analyze the dif-
ferent clusters to get an idea of which of the residues differ between the clusters and
which stay the same throughout and between molecular dynamics simulation. A
novel method to analyze multiple sequence alignment was adapted for that task153.
Proteinkeys
Proteinkeys153 is a method to identify specificity residues in sets of proteins related
by evolution, where the specificity residues are defined as those conserved within a
subfamily (cluster) but differ between subfamilies, that is encode functional diversity.
This method can be adapted to analyze the clusters obtained by Affinity propagation.
The adapted proteinkeys method is as follows; The total number of permutations
in a column i of cluster k is given by a combinatorial formula:
Zi, k =
Nk!
∏α=1,..,n Nα,i,k!
(4.13)
Where Nk is the number of members in each cluster k, Nα,i,k is the number of
residues with a value of type α in column i of cluster k.
Then combinatorial entropy is used as an additive measure for comparing different
distributions of fingerprint values between clusters:
Si =∑
i
lnZi,k (4.14)
Specificity residues are those that have similar properties within a cluster but differ
between clusters. At one extreme the column specific Si is zero if values of one type
populate this column. So Si = 0 for properties that are the same or perfect specificity
residues in column i.
At the other extreme, uniformly distributed residues, Si has a maximal value given
by the background entropy S˜i:
S˜i =∑
k
lnZ˜i,k =∑
Nk!
∏α=1,..,n N˜α,i,k!
(4.15)
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Where N˜α,i,k is the expected number of the residue of a type α in the column i of
cluster k, provided that all the residues in the column are uniformly mixed, or:
N˜α,i,k =
NkNα,i
N
(4.16)
where Nα,i,k is the number of the residues of a type α in column i and N is the total
number of cluster members. Since N˜α,i,k as shown in equation 5.17 can be non integer
numbers, N˜α,i,k! is calculated using the relation X! = Γ(X+ 1).
As the numerical measure of order over disorder, the entropy difference can be
calculated: ∆Si = Si − S˜i
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5.1 How Inaccuracies in Protein Structure Models
Affect Estimates of Protein-Ligand Interactions
Thorsteinsdottir HB, Schwede T, Zoete V, Meuwly M.
Proteins. (2006) 65:407-23
The work presented here addresses one of the bottlenecks of structure-based drug
design, which is the limited availability of experimentally determined protein struc-
tures. In the cases where no protein structures are available, an alternative can be
to build a homology model, but they need to be sufficiently accurate to be of use
for drug discovery. Validation of these homology models is therefore a crucial as-
pect in drug development. One important question we aim to address is how errors
and inaccuracies of the homology models affect the subsequent molecular modeling
of protein-ligand interaction. We study this by utilizing a well characterized protein
system with ligands whose binding free energy has been determined experimentally.
By doing this we can study the effects of sequence variations and introduce system-
atic errors in the protein model. This enables us to simulate the typical errors that
occur during homology modeling, e.g. sub-optimal template selection or side chain
placement, to quantify the effect on ligand binding affinity and ranking of ligands
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How Inaccuracies in Protein Structure Models Affect
Estimates of Protein–Ligand Interactions: Computational
Analysis of HIV-I Protease Inhibitor Binding
Holmfridur B. Thorsteinsdottir,1,2 Torsten Schwede,1,2 Vincent Zoete,3 and Markus Meuwly4*
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ABSTRACT The influence of possible inac-
curacies that can arise during homology modeling
of protein structures used for ligand binding stud-
ies were investigated with the molecular mechan-
ics generalized Born surface area (MM-GBSA)
method. For this, a family of well-characterized
HIV-I protease–inhibitor complexes was used. Vali-
dation of MM-GBSA led to a correlation coefficient
ranging from 0.72 to 0.93 between calculated and
experimental binding free energies DG. All calcu-
lated DG values were based on molecular dynam-
ics simulations with explicit solvent. Errors intro-
duced into the protein structure through mis-
placement of side-chains during rotamer modeling
led to a correlation coefficient between DGcalc and
DGexp of 0.75 compared with 0.90 for the correctly
placed side chains. This is in contrast to homology
models formembers of the retroviral protease family
with template structures ranging in sequence iden-
tity between 32% and 51%. For these protein models,
the correlation coefficients vary between 0.84 and
0.87, which is considerably closer to the original
protein (0.90). It is concluded that HIV-I low se-
quence identity with the template structure still
allows creating sufficiently reliable homology mod-
els to be used for ligand-binding studies, although
placement of the rotamers is a critical step during
themodeling. Proteins 2006;65:407–423. VC 2006Wiley-
Liss, Inc.
Key words: molecular dynamics; homology model-
ing; HIV; ligand binding
INTRODUCTION
One of the bottlenecks of structure-based drug design
is the limited availability of experimentally determined
protein structures. In virtual screening, a widely used
approach in drug discovery, a library of small molecules
is docked into the active sites of proteins. Accurate and
reliable atomic representations of the receptor proteins
are required to correctly model possible ligand–protein
interactions. In spite of advances in X-ray crystallogra-
phy and NMR protein determination techniques, there
is still a considerable gap between the number of
sequences and structures available. Although the Uni-
Prot nonredundant protein sequence database1 contains
just below 2 million sequences, the Protein Data Bank
(PDB)2 contains about 12,500 different structures (both
numbers based on 90% sequence identity). Thus, for
most protein sequences, there are no experimental struc-
tures available. In such cases, homology models can pro-
vide a valuable alternative. Homology modeling (HM)
uses known experimental structures as a template to
create a three-dimensional model for a similar protein
for which the structure is unknown.3 This is possible
because structures within a given protein fold family are
better conserved than their sequences.4 Validation of
homology models is a crucial aspect in drug develop-
ment. One important question is to assess to what
extent errors and inaccuracies of the homology models
affect the subsequent molecular modeling of protein–
ligand interactions. To address this question, we have
selected the HIV-I protease system.
HIV-I protease is an essential component in the life
cycle of the HIV virus. The function of the protein is to
cleave viral polyproteins so that the viral particles can
mature. Because of this important role, HIV-I protease
is one of the main targets for AIDS therapy, and cur-
rently there are four inhibitors of the HIV-I protease in
clinical use and more that are undergoing clinical tri-
als.5 HIV-I protease is a member of the aspartyl protease
family.6 The protein is active as a homodimer of two
identical 99 amino acid chains. More than 150 experi-
mental structures are publicly available in the Protein
Data Bank (http://www.rcsb.org/pdb/) or the HIV PR
database (http://mcl1.ncifcrf.gov/hivdb/).
In a recent study, the binding free energies of 16 HIV-
I protease inhibitor complexes were investigated compu-
tationally using molecular dynamics simulations and
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techniques based on a linear interaction energy (LIE)-
like method. A favorable correlation of 0.91 between cal-
culated and experimental values was observed.7 In the
present study, a protocol based on the molecular
mechanics-generalized Born surface area (MM-GBSA)
approach8 to calculate binding free energies of the same
16 HIV-I protease inhibitor complexes is first investi-
gated. Such an efficient approach to estimate ligand
binding free energies allows studying the effects of var-
iations in the protein structure on the affinity calcula-
tions. Here, MM-GBSA is first validated and then
applied to explore the effect of structural variations in
view of typical inaccuracies that can occur during pro-
tein structure homology modeling.
The ligands used in our study have different chemical
properties; there are diol inhibitors and analogues of
those ligands with thiophenyl ether and phenol–amide
substituents, penicillin-derived, amides and amino sulfo-
namides. The experimental binding free energies of
ligands differ by 5 kcal/mol, and the experiments were
carried out by a number of different groups. Where
given, errors in experimental binding free energies are
estimated between 10 and 20%.9,10 Here we attribute a
conservative error of 10% for all the experimentally
determined binding free energies.
The present work is structured as follows. First, the
computational and theoretical methods used are pre-
sented. Next, the MM-GBSA approach to estimate free
energies and to rank a number of ligands is validated
with respect to experimental data. The results are ana-
lyzed in detail and in a next step, MM-GBSA is applied
to erroneous protein structures. They come either from
suboptimally placed side chains or from structures based
on homology models with different degrees of sequence
similarities. Finally, the results are discussed in view of
experiments and other modeling studies.
THEORETICAL METHODS
For the present study, 16 well-characterized inhibitors
(Figs. 1 and 2) of the HIV-I protease were selected. Crys-
tal structures for each of the 16 ligands complexed to
HIV-I protease and experimental values for the binding
free energy are available. Table I provides PDB acces-
sion code, resolution, and the experimentally determined
binding free energies for each of the 16 ligand–protein
complexes. In all complexes, the protease corresponds to
the wild type sequence.
As shown by Zoete et al.,23 the conformation for these
16 ligand–protein complexes is well conserved, with the
most rigid part around the binding site of the ligand
(Table I reports the root mean square deviations (RMSD)
of the backbone atoms for each of the ligand–protein
complexes to the reference structure of 1HVI).
Molecular Dynamics Simulations
The molecular dynamics (MD) simulations were per-
formed using CHARMM24 version 30b1 and the ‘‘all-atom’’
Fig. 1. Structures of ligands 1–8 used for the present study.
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force field CHARMM22.25 The starting coordinates for the
MD simulations were the coordinates of the 16 ligands in
their experimentally determined structures, the ones of
1HVI, and 1OHR, or the structures obtained from homol-
ogy modeling, respectively. All protein–ligand complexes
were superimposed, and the coordinates of the ligands
were transferred into the chosen reference structures.
Partial atomic charges and the all-hydrogens parameters
for van der Waals and bonded energy terms for the 16
ligands have been previously determined.7 Depending on
the inhibitor, either residue Asp25 or Asp250 of the HIV-I
protease can be protonated in a complex.16,26–28 In our
work, to facilitate comparisons, protonation of Asp25 for
all protein–ligand complexes is assumed.
Each of the protein–ligand complexes was solvated
with a water sphere of radius 24 A˚, centered at the oxy-
gen O48 atom of ligand A77003, which is in the center
of the protein–ligand complex. Depending on the ligand
present, a total of 2880–2985 water molecules were
added, resulting in a system of 6104–6208 atoms. The
stochastic boundary method was used29 with a reaction
region of 20 A˚ and a buffer region of 4 A˚. Electrostatic
interactions were shifted and calculated with a 12 A˚ cut-
off and the van der Waals interactions were switched at
long range.
The water molecules were equilibrated at 300 K for 80
ps with the protein and ligand fixed. Then the complex
was minimized for 200 steps of steepest descent minimi-
zation and then heated and equilibrated from 0 to 300 K
during 150 ps. Harmonic restraints of 5 kcal/mol ini-
tially applied to the ligand and protein atoms within the
reaction region were slowly removed during the heating.
At 300 K, all restraints were removed from the reaction
region. Heavy atoms in the buffer region were coupled
to a heat bath, using the Langevin equation of motion
and a 250 ps1 friction constant.30 A friction constant of
Fig. 2. Structures of ligands 9–16 used for the present study.
TABLE I. PDB Codes, Ligand Names, and the
Experimentally Determined Binding Free Energy
of all the Ligand–Protein Complexes
PDB Ligand
Resolution
(A˚)
RMSD
(A˚)a DGexpbind Ref.
1HVL A76889 1.80 0.15 14.16 [11]
1HVK A76928 1.80 0.18 15.60 [11]
1HVI A77003 1.80 0.00 15.54 [11]
1HVJ A78791 2.00 0.14 16.22 [11]
1DIF A79285 1.70 0.17 15.17 [12]
1OHR AG1343 2.10 0.21 12.38 [13]
1AJX AHA001 2.00 0.68 11.26 [14]
1AJV AHA006 2.00 0.75 10.98 [15]
1HTF GR126045 2.20 0.55 9.82 [15]
1HPX KNI272 2.00 0.60 16.02 [16]
1HSG L735524 2.00 0.62 13.21 [17]
2BPV L738317 1.90 0.61 10.51 [18]
1HBV SB203238 2.30 0.60 9.06 [19]
1HOS SB204144 2.30 0.57 12.17 [20]
1HPS SB206343 2.30 0.64 13.12 [21]
1HPV VX478 1.90 0.64 13.12 [22]
Energies are in kcal/mol.
aRMSD of backbone atoms to the reference structure 1HV1.
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62 ps1 was applied to the water oxygens. MD simula-
tions used for the analysis were carried out at 300 K,
using Langevin dynamics during 500 ps with a time step
of 1 fs. For the validation simulations (ligands in their
respective protein) all trajectories were extended to 2 ns.
Binding Free Energy Estimation
Frames from the MD simulation were extracted every
1 ps, which gives a total of 500 frames per trajectory
(2000 for the validation runs). The binding free energy
DGbind was calculated using the MM-GBSA approach,
8
according to the thermodynamic cycle shown in Figure 3.
DGbind can be decomposed into a sum of the gas phase
contribution, DEvacuo, the desolvation energy upon bind-
ing, DGdesolv, and an entropy contribution, TDS:
DGbind ¼ hDEvacuoi þ hDGdesolvi  hTDSi ð1Þ
The brackets indicate ensemble averages of the quanti-
ties calculated from the 500 frames along the trajectory.
In this approach, the gas phase contribution is equal to
the van der Waals (DEvdw) and electrostatic (DEelec) in-
teraction energies between the ligand and the protein,
and the difference of the internal energy, DEintra, be-
tween the complex and the separated ligand/protein sys-
tem (deformation energy). However, since we only use
the trajectory of the complex, DEintra ¼ 0, and it does not
enter the subsequent calculations.
The desolvation energy, DGdesolv, is the difference
between the solvation energy of the complex, DGCsolv, and of
the ligand and protein, DGLsolv and DG
P
solv, respectively. The
solvation for all three systems can be further divided into
electrostatic (DGsolv,elec) and nonpolar (DGsolv,np) contribu-
tions. The electrostatic contribution to the solvation free
energy (DGsolv,elec) was estimated from the analytical Gen-
eralized Born (GB) GB-MV2 model implemented in
CHARMM.31,32 Calculations using this model are much
faster compared with those solved numerically using the
Poisson equation (as required for PBSA calculations33,34)
and were found to reproduce solvation energies with 1% ac-
curacy compared with the Poisson model. Recent results
show that the deviation in the desolvation energy between
the GB-MV2 model and the PB model is constant, which
means that the use of GB-MV2 does not alter the ranking
of the ligands.35 Also, using the GB-MV2 model allows for
easier decomposition of the electrostatic energy than is pos-
sible with PBSA. The nonpolar contribution is assumed to
be proportional to the solvent accessible surface area
(SASA). This approximation is based on the observation
that the solvation of saturated nonpolar hydrocarbons is lin-
early related to the SASA.36 A value of 0.0072 kcal/mol A˚2
was used for the surface tension.8,37,38 The solvent acces-
sible surface areas were calculated analytically with
CHARMM, with a solvent probe radius of 1.4 A˚.
The entropic contribution, TDS, corresponds to the
contributions of translational, DStrans, rotational, DSrot,
and vibrational, DSvib, entropies:
 TDS ¼ TDSvib  TDStrans  TDSrot ð2Þ
where each of these terms is calculated from standard
equations of statistical mechanics.39,40 The entropic contri-
bution is required for calculating absolute binding free
energies. TDStrans and TDSrot are functions of the mass
and moments of inertia, while TDSvib is calculated from a
normal mode analysis.40 Since the normal mode calcula-
tions are computationally very demanding, TDS was
only averaged over 20 frames of the trajectory. The
VIBRAN module of CHARMM was used to determine the
normal modes and normal mode frequencies. The normal
modes were calculated in vacuo for a fully minimized-
structure of the molecule (complex and protein:ligand)
with a distance-dependent dielectric, e ¼ 4r. The minimi-
zation was performed using the Adopted Basis Newton-
Raphson algorithm, until the root mean square of the
energy gradient reached 107 kcal/mol A˚. This gradient
value is expected to give only real frequencies.40 The mini-
mized structures were also used to calculate the moments
of inertia. Since TDSvib is computationally very demand-
ing to calculate and as we are only interested in relative
energies, the entropic term was calculated for all the
ligands docked in the reference protein 1HVI to verify
that a ranking of the ligands can be obtained without
including the entropic term. Thus, the working equation
to estimate binding free energies is
hDGbindi ¼ hDEeleci þ hDEvdwi þ hDGdesolv;eleci þ hDGdesolv;npi
ð3Þ
Binding Free Energy Decomposition
To estimate which residues of the protein make the
most important contributions to the ligand binding, an
energy decomposition of the binding free energy was per-
formed. For the electrostatic interaction energy between
the residues of the protein and the ligand, one half of the
energy is attributed to the ligand and the other half to
the protein residue. The contribution of atom i to the total
electrostatic interaction energy is given by
Eielec ¼
1
2
X
j
qiqj
rij
ð4Þ
where j loops over all the atoms of the component to
which i does not belong, that is, over the protein if i
Fig. 3. The thermodynamic cycle used to estimate the binding free
energy of the ligand–protein complexes in vacuo, DEvacuo, and in water,
DGbind. DG
P
solv, DG
L
solv, and DG
C
solv are the solvation energies of the pro-
tein, ligand, and complex, respectively.
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belongs to the ligand, or over the ligand if i belongs to the
protein. rij is the distance between atoms i and j and qi
and qj are their atomic charges. For the pairwise van der
Waals interactions between the protein and ligand, one
half is attributed to each atom involved in the interaction.
The solvent accessible surface area of atom i in the
complex, SASAi,C, and in the protein, SASAi,P, and
ligand, SASAi,L, is calculated by CHARMM. The contri-
bution of atom i to the nonpolar desolvation term is thus
DGinp,solv ¼ r(SASAi,C  (SASAi,P þ SASAi,L)). The elec-
trostatic solvation term is calculated using the GB-MV2
approach, which uses the expression of Still et al.38 for
the electrostatic solvation term:
DGelec;solv ¼ k
X
i;j
qiqjffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
r2i;j þ aiaj expðr2i;j=KsaiajÞ
q ð5Þ
where k ¼ 166.0(e1solute – e1solvent). esolute and esolvent are
the dielectric constant, that is, 1 and 80, respectively,
and ai and aj are the Born radii of atoms i and j, calcu-
lated with the GB-MV2 approach. i and j loop over all
atoms of the system. The constant Ks is equal to 8 in
the GB-MV2 approach. The contribution of atom i to
DGXelec,solv can therefore be written as
DGi;Xelec;solv ¼ k
q2i
ai
þ 1
2
k
X
j 6¼i
qiqjffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
r2i;j þ aiaj expðr2i;j=KsaiajÞ
q ð6Þ
where X stands for the complex, the protein, or the ligand.
The contribution of atom i to the electrostatic desolva-
tion energy is DGielec,desolv ¼ DGi,Celec,solv  (DGi,Pelec,solv þ
DGi,Lelec,solv). Adding all these atomic contributions over the
atoms of a given residue or side chain or backbone frag-
ment yields its contribution to the total binding free
energy.
Homology Modeling
Homology modeling (HM) aims at predicting the
three-dimensional structure of a given protein based on
information derived from experimentally determined
structures of homologous proteins. HM methods consist
of four steps: template selection, alignment, model build-
ing, and model evaluation. For a given target sequence,
templates are selected from a database of known struc-
tures. In general, sequence similarity between the target
and template is a good indicator for template selection.
Next, the template sequence(s) and the target sequence
are aligned. This is a crucial step in HM, since an incor-
rect alignment leads to errors that cannot be corrected
later on. Typically, for closely related proteins with
sequence identity above 50%, the generated alignments
are correct, in particular for the better conserved active
sites of a protein. For lower sequence identities, it is ad-
visable to manually inspect the alignment to ensure that
insertions and deletions have not been placed in struc-
turally unfavorable regions.41 Based on the template
structure(s) and the alignment between the target and
template(s), a model for the target sequence can be built.
To assist with the homology modeling, automated meth-
ods are available. In general, they can be divided in
methods based on rigid fragment assembly such as
SWISS-MODEL42,43 or Composer,44 and spatial restraint
methods as used in Modeller.45
Errors in HM can occur at various stages. Typically,
errors in models increase with decreasing sequence simi-
larity between the target and template. A low sequence
identity between the target and template sequences
increases the risk of alignment errors and incorrect side
chain placements. Template selection is an important
factor in homology modeling. Minor or major structural
variations between different templates can influence the
subsequent modeling. For example, the template struc-
ture can be in the apo or complex forms, open or closed
conformation, and have different bound ligands.
In the present work, homology models for HIV-I prote-
ase were based on template structures from (a) Simian
Immunodeficiency Virus protease (1SIP, 2.3 A˚ resolu-
tion) sharing 51% sequence identity,46 (b) HIV-2 protease
(1IDA, 1.7 A˚ resolution) sharing 48% sequence iden-
tity,47 (c) Rous Sarcoma Virus Protease (1BAI, 2.4 A˚ re-
solution) sharing 43% sequence identity,48 (d) equine in-
fectious anemia virus protease (1FMB, 1.8 A˚ resolution)
sharing 32% sequence identity,49 and (e) Feline Immuno-
deficiency Virus (3FIV, 1.85 A˚ resolution) sharing 32%
sequence identity with HIV-I protease.50
The homodimeric assembly of the template 1FMB was
generated by applying crystallographic symmetry. In
this first approach, the best possible models were gener-
ated using a pairwise structural alignment between the
target and the template structure of the reference pro-
tein 1HVI as starting alignments. The sequence align-
ments used in the modeling are provided in Figure 4.
Homology models were built using the comparative mod-
eling server SWISS-MODEL42 using the project submis-
sion mode.51 All models were validated using Procheck52
to assess the stereochemical quality of the models and
Anolea mean force potential assessment53 to evaluate
the environment of heavy atoms. For the model based
on 1SIP, 1FMB, and 1IDA, no residues with bad stereo-
chemistry were found in the proximity of the binding
pocket. The model based on 1BAI had one residue
(Met145) within 5 A˚ of the ligand in the ‘‘generously
allowed’’ region of the Ramachandran plot. The model
based on 3FIV contained two residues (Val82 and
Val181) within 5 A˚ of the ligand in the ‘‘disallowed’’
region.
Accurate prediction of side-chain conformation is
expected to play an important role in HM for drug-
design purposes. Most comparative modeling methods,
such as SWISS-MODEL or Modeller, extract information
about side chain placement from template structures.
Rotamer libraries are used to assist the modeling of side
chain conformations when only insufficient template in-
formation is available. To assess the influence of correct
rotamer placement for calculating the relative binding
free energy of ligands, all side-chain conformations were
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regenerated from a backbone structure of 1HVI using
the program SCWRL.54
RESULTS
The main objective of the present study is to validate
and apply a method for assessing the effects of struc-
tural variation in protein structures on the prediction of
ligand-binding affinities. Structural variations in atomis-
tic protein models used for drug development may occur
for several reasons. The protein structure at hand may
have been cocrystallized with a different ligand giving
rise to induced fit movement of different extent. In cases
where no experimental protein structures are available,
HMs are often used. It is known that HMs have limita-
tions in predicting the correct conformation of the real
structure. To assess the effects of such structural varia-
tions for ranking a set of ligands, a computationally effi-
cient means to calculate binding free energies is required.
Previous work on the same 16 ligands was carried out
with the LIE-like approach together with simulations in
implicit solvent. Here, the MM-GBSA approach is used
to study the impact of possible accuracies of HM on
ligand ranking. First, the increased computational
power available allows MD simulations, with explicit sol-
vent and stochastic boundary conditions to be carried
out. Second, the previous LIE-like approach uses
weighted energy terms to estimate absolute binding free
energies. As a result, the LIE-like equation is not uni-
versal and depends on the protein–ligand complexes
studied. Here, we are primarily interested in ranking
the different ligands for which relative free energies are
usually sufficient. Also, it is preferable to use a univer-
sal scoring method, which is independent of adjustable
parameters.
Validation of MM-GBSA
To validate the calculation of DG as described in the
Methods section, DG for the ligands in their respective
experimental protein structures (see Table II for an over-
view of all calculated binding free energies) was calcu-
lated. These values are based on 500 snapshots from 500
ps trajectories for each of the ligands in their respective
proteins with explicit solvent. A correlation of R ¼ 0.72 
0.04 between DGexp and DGcalc was observed. However,
there are two ligands (A78791 and KNI272) for which the
Fig. 4. Sequence alignment used in the homology modeling.
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comparison is less favorable. The correlation without
these two improves to R ¼ 0.87  0.02. Figure 5(A,B)
shows the correlation (with and without the ligands
A78791 and KNI272) of the calculated binding free
energy DGcalc for each ligand. The uncertainty in the cor-
relation coefficients R was calculated from a leave-one-
out procedure. The two outliers are discussed in more
detail in the Appendix.
TABLE II. Experimental and Calculated Binding Free Energies of the 16 Ligands
Ligand Own protein 1HVI
Sub-opt
rotamer
1SIP
(HM)
1FMB
(HM)
1BAI
(HM)
3FIV
(HM)
1IDA
(HM) Exp
A76889 70.4  7.9 71.8  10.1 83.8  7.8 65.4  8.4 66.2  7.8 66.8  8.2 63.3  8.1 60.4  9.0 14.2
A76928 77.3  8.1 79.2  8.0 82.6  7.0 74.0  7.7 70.4  8.3 71.9  12.6 75.3  8.6 79.6  8.0 15.6
A77003 76.2  7.3 76.2  7.3 84.3  6.0 65.9  8.2 75.4  7.4 76.6  8.9 76.9  8.4 76.2  7.9 15.5
A78791 65.4  7.8 67.6  7.5 55.0  8.9 56.3  8.4 58.8  8.4 71.2  7.1 60.7  8.6 66.0  7.8 16.2
A79285 78.0  6.4 77.0  7.9 64.5  6.5 85.3  6.9 80.1  6.5 80.2  6.3 66.0  7.3 65.0  9.6 15.2
AG1343 62.7  6.0 58.0  6.4 60.4  5.5 54.6  8.0 53.9  6.5 54.4  6.2 49.9  7.4 57.9  6.9 12.4
AHA001 54.4  7.0 53.6  6.5 59.0  6.4 46.7  10.0 55.1  6.5 51.7  6.6 52.4  6.9 54.9  6.3 11.3
AHA006 62.1  5.6 55.1  6.3 58.9  5.5 60.5  6.0 58.9  6.7 62.8  5.5 51.5  6.6 55.7  6.8 11.0
GR126045 37.6  7.6 43.8  6.2 42.0  10.2 33.6  7.7 50.9  7.2 51.4  5.5 42.7  7.1 47.4  6.1 9.8
KNI272 59.6  9.6 62.0  8.6 60.0  6.4 56.3  8.2 60.1  6.8 61.2  6.6 62.4  11.2 63.0  6.9 16.0
L735524 77.0  7.2 50.2  7.3 67.3  6.1 64.2  6.5 60.0  6.5 64.6  6.5 50.2  7.5 71.1  8.4 13.2
L738317 58.8  6.5 48.9  7.6 69.1  5.4 55.7  7.5 56.3  6.6 57.7  6.6 42.6  9.7 57.9  9.8 10.5
SB203238 53.8  8.5 40.5  8.7 48.5  7.2 38.9  10.2 43.5  6.4 34.0  8.0 30.0  8.1 50.6  7.5 9.1
SB204144 29.7  11.9 58.2  10.2 50.8  9.2 58.5  8.0 59.5  9.6 57.4  8.2 33.6  9.5 48.8  11.8 12.2
SB206343 59.7  10.5 56.9  8.0 57.8  6.1 63.4  6.9 69.6  6.6 70.5  7.4 55.1  8.8 62.6  7.1 13.1
VX478 55.7  5.7 50.3  6.2 54.3  6.2 49.4  6.8 53.6  6.1 52.0  6.9 52.2  8.2 53.9  6.7 13.1
Energies are in kcal/mol.
Fig. 5. Correlation between the experimentally determined binding free energy and the calculated one for the
ligands in their respective structures, with (A) and without ligands A78791 and KNI272 (B), and in reference struc-
tures 1HVI (C) and 1OHR (D). Energies are in kcal/mol. Error bars are 10% for the experimental values (see text).
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To relate differences in ligand-binding-free energies
unequivocally to protein–ligand interactions (see discus-
sion below) without contamination from differing protein
conformations far away from the active site, we calcu-
lated DG for the 16 ligands in two different, arbitrarily
chosen reference structures: 1HIV and 1OHR. This is
similar to ‘‘crossdocking’’ in docking studies where a
ligand is docked into a protein structure complexed with
a different ligand or from the apo protein.55 The
approach is also similar in spirit to the ‘‘same trajectory
method’’ (STM) used for estimating the dimerization
energy of the insulin dimer.35 Ligand binding energies
are reported in Table II, and Table III gives the decom-
position of <DGbind> for the reference structure 1HVI
into the individual contributions from Eq. (3). The
observed correlation between DGexp and DGcalc for 1HIV
and 1OHR was 0.85  0.02 and 0.78  0.03, respectively.
As in the previous simulations, the same two ligands
(A78791 and KNI272) failed to correlate well, and omit-
ting these improves the correlation to 0.90  0.02 and
0.93  0.01, respectively [Fig. 5(C,D)].
However, for the binding free energies for ligands in
their respective protein structures, we observed a corre-
lation of 0.72 between calculated and experimental val-
ues, which is not particularly good. Part of the shortcom-
ings may be related to the simulation time of 0.5 ns. To
test the influence of longer simulation times, MD simu-
lations were carried out for 2 ns for the 16 ligands in
their respective proteins. Analyzing the correlation coef-
ficient as a function of time (see Fig. 6) without the two
outliers, R stabilizes around 0.85  0.03 which is also
the value after 500 ps. Including A78791, R ¼ 0.81 
0.03 is reached, while including both outliers (A78791
and KNI272) R drops to 0.57  0.07. Inspection of the
trajectory of KNI272 reveals that after 750 ps the hydro-
gen bonds within the active site reorganize and lead to a
considerable reduction in the electrostatic interaction
between the ligand and the protein. This is discussed in
more detail for A78791 in the appendix. In addition, Fig-
ure 6 shows the temporal evolution of the R for the two
reference structures, 1HVI and 1OHR, including and
excluding the outliers A78791 and KNI272. As for the
simulation in the respective protein, R reaches a plateau
after about 300 ps. The behavior of R as a function of
time for simulations in the respective protein suggest
that a simulation time of 500 ps is appropriate unless
structural changes occur in the active site (as for
KNI272). Such effects are, however, relatively straight-
forward to detect as illustrated in Figure 6.
Treating each ligand in its proper protein environment
introduces a further source of uncertainty. Because the
present simulations are carried out with stochastic bound-
ary conditions, regions outside the solvation sphere do not
TABLE III. Energy Contribution for the 16 Ligands in the Reference
Structure 1HVI
Ligand VDW Elec. Elec. desolv. Nonpolar desolv. Total
A76889 70.8  4.3 80.2  8.5 88.2  6.8 9.0  0.1 71.8  10.1
A76928 77.9  4.1 78.1  9.8 85.9  6.5 9.1  0.1 79.2  8.0
A77003 74.3  4.3 87.4  6.8 94.4  6.6 9.0  0.1 76.2  7.3
A78791 78.4  4.0 57.7  6.3 77.4  6.6 9.0  0.1 67.6  7.5
A79285 80.0  4.4 81.9  7.7 94.0  7.5 9.2  0.1 77.0  7.9
AG1343 63.4  3.6 55.1  4.6 68.3  6.1 7.8  0.1 58.0  6.4
AHA001 54.8  3.6 54.3  5.6 62.8  5.9 7.3  0.1 53.6  6.5
AHA006 61.3  3.4 51.1  4.3 64.8  5.4 7.4  0.1 55.1  6.3
GR126045 51.4  3.4 53.3  5.3 67.6  5.8 6.7  0.1 43.8  6.2
KNI272 69.6  3.6 62.1  8.2 77.7  6.2 8.0  0.1 62.0  8.6
L735524 67.3  3.4 46.2  5.4 71.6  7.1 8.4  0.1 50.2  7.3
L738317 64.1  3.4 50.6  5.6 74.0  6.7 8.2  0.1 48.9  7.6
SB203238 59.2  4.3 40.5  10.6 67.4  7.1 8.2  0.1 40.5  8.7
SB204144 67.6  5.3 60.1  7.3 78.1  7.1 8.7  0.1 58.2  10.2
SB206343 59.2  3.8 68.6  5.7 79.0  7.3 8.1  0.1 56.9  8.0
VX478 51.9  3.4 51.9  5.0 60.3  5.2 6.9  0.1 50.3  6.2
Energies are in kcal/mol.
Fig. 6. The correlation coefficient R calculated for each ligand in its re-
spective protein (black), and in each of the reference structures 1HVI
(red) and 1OHR (green). Values are calculated every 50 ps along the 500
ps and 2 ns trajectories, respectively. Results for all 16 ligands are the
solid curves, while dashed curves are for the ones excluding both outliers.
The blue dotted line is for the simulations in the respective protein exclud-
ing the outlier KNI272. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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move during the MD simulations. However, energy terms
in MM-GBSA are evaluated between all atoms of the sys-
tem. If the ligands are docked into one reference structure
(e.g., 1HIV), the structure of the most distant part is
invariant. This is not the case if ligands are docked into
their proper protein structures; there, each ligand has an
individual, slightly different long-range environment which
influences the interaction energies and thus the ranking.
This effect is illustrated in Table IV, where the binding
free energy decomposition for the ligands L738317,
SB203238, and SB204144 is shown. When docked into
the reference protein, the ranking of the three ligands is
in agreement with experiment, while docking them into
their respective structures changes the ranking.
Previous simulations of three HIV-I protease inhibitor
complexes used 1 ns of MD simulations with calculated
and experimental binding free energies of (30.1, 45.0,
45.0) kcal/mol versus (14.2, 13.4, 14.6) kcal/mol
for (SQV, IDV, QF34), respectively, which yields R ¼
0.2.56 It is also of interest to compare the binding free
energy previously determined using a LIE-like method
and the binding free energies calculated here. The corre-
lation between the two computational approaches is 0.89,
including both A78791 and KNI272, which is reassuring.
It is worthwhile noting that the same two ligands were
also amongst the outliers when the more accurate LIE-like
method for estimating DGcalc was used.
7
It was also tested whether including entropic effects
reduces the observed deviations. The entropic contribu-
tion to DGcalc was calculated for the ligands A78791 and
KNI272 for each of the ligand–protein complexes in the
reference protein 1HVI for 20 frames along the molecu-
lar dynamics trajectory. However, including the entropic
term in the binding free energy does not improve the
correlation, and the ligands A78791 and KNI272 are still
outliers.
Application to Assess Comparative Models
Based on the good correlation between experimentally
determined and calculated binding free energies for 14
of the 16 ligands in their respective complex structures
and docked into the reference proteins 1HVI and 1OHR,
MM-GBSA as applied here is a computationally feasible
and sufficiently accurate approach to rank ligands based
on DG values. The molecular dynamics and binding free
energy calculations for a single protein–ligand complex
takes 48 h on a 2.6-GHz AMD Opteron computer using
a single CPU. This makes the procedure applicable to
assess the effects of typical errors observed in HM to
computing binding free energies of ligand–protein com-
plexes. For comparison, a previous study of peptide ana-
logue binding to HIV-I protease reports a timing of 30 h
for the determination of one binding constant on a clus-
ter of Linux computers with 1.3-GHz Intel Pentium III
processors using one CPU for the MD simulations and
two CPUs for solving the Poisson equation.57 These sim-
ulations used a weighted histogram analysis to estimate
the free energy of binding and were carried out for 5500
time steps in implicit solvent with fixed protein atoms
further than 5 A˚ away from any ligand atom. The corre-
lation coefficient from this study is R ¼ 0.89 for the five
peptide analogues considered.
The correlation between calculated and observed bind-
ing free energies was found to be satisfactory for 14 out
of the 16 ligands. Possible reasons for the observation
that A78791 and KNI272 do not correlate with experi-
mental observations are discussed in more detail in the
Appendix. In the following, the performance of various
homology models and perturbed backbone structures
will be assessed. Since the two outliers could obscure
the major point of this investigation, which is to assess
the influence of possible inaccuracies in the protein
structure on estimates for ligand affinities, the results
are discussed for the validated set of the 14 ligands that
correlate well with experiment. However, all calculations
were carried out for the 16 ligands and correlation coef-
ficients are given for both, the set of all 16 ligands and
the set without the two outliers.
Suboptimal rotamer placement
A protein structure model with suboptimally placed
side-chain conformations was generated by remodeling
all side chains based on the backbone of the reference
structure 1HVI using SQWRL.54 Residues within 5 A˚ of
the ligand superimpose to 1.26 A˚ (backbone and side-
chains) compared with the structure of 1HVI. The ligands
were docked in this suboptimal rotamer model and the
TABLE IV. Calculated Binding Free Energies of the Ligands L738317, SB203238,
and SB204144 for Both the Reference Structure 1HVI and the Respective Structure
Ligand VDW Elec. Elec. desolv. Nonpolar desolv. Total
Reference protein (1HVI)
L738317 64.05 50.60 74.03 8.23 48.85
SB203238 59.22 40.47 67.44 8.23 40.48
SB204144 67.58 60.06 78.10 8.66 58.21
Respective structures
L738317 67.45 63.93 80.79 8.17 58.78
SB203238 67.83 44.52 66.82 8.24 53.76
SB204144 62.78 43.40 87.77 8.26 29.68
Energies are in kcal/mol.
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relative DG calculated as described before. Figure 7(A)
shows the correlation between the experimentally deter-
mined binding free energies and the calculated ones. A
correlation of 0.75  0.04 (0.54  0.05 for all 16 ligands)
is obtained, which compares with a correlation of 0.90
(0.85) for the reference protein. Thus, the suboptimal
rotamer model destroys the correlation for some of the
ligands, in particular for ligands A79285, SB203238, and
L738317. Table V analyzes DG for these three ligands, in
comparison with the binding free energies in the refer-
ence structure of 1HVI. For A79285, DG decreases by
12.5 kcal/mol with electrostatics and desolvation ener-
gies contributing most to the difference, while for
L738317 a stabilization of about 20 kcal/mol is found,
again mostly from the electrostatics and desolvation
energy terms. However, for SB203238 the favorable con-
tribution of 8 kcal/mol originates mostly from the van der
Waals interactions.
Fig. 7. Correlation between observed and calculated ligand-binding energies for the suboptimal protein struc-
tures; (A) the rotamer structure, (B) homology model based on 1SIP (51% sequence identity), (C) 1IDA (48%
sequence identity), (D) 1BAI (43% sequence identity), (E) 1FMB (32% sequence identity), (F) 3FIV (32% sequence
identity). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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It is instructive to consider the binding free energy
decomposition for residues within 5 A˚ of the active site.
This gives an impression of the origin for the free energy
differences between the calculations in the reference struc-
ture and the rotameric model. Figure 8 shows the differ-
ence DDG in total energy contributions between the three
ligands in the reference structure of 1HVI and the subopti-
mal rotamer placement. Considerable differences (larger
than 2 kcal/mol) are found for residues Asp29, Arg87,
Asp250, and Asp290. For Asp250 and Asp290, the same
rotamer conformation as in the reference structure is gen-
erated with SQWRL. The RMSD difference between the
side-chains generated with SQWRL and those of the refer-
ence protein is only 0.45 A˚ and 0.36 A˚ respectively. It is
only for the ligand L738317 that a considerable difference
is observed between the rotamer model and the reference
protein, in both cases resulting in better electrostatic inter-
actions between the residues and the ligand. However, for
Asp29 and Arg87, a different rotamer conformation is gen-
erated. The RMSD difference between the side-chains gen-
erated with SQWRL and those of the reference protein is
2.3 A˚ and 2.0 A˚, which results in considerable difference
in energy contribution of these two residues for all three
ligands A79285, SB203238, and L738317.
Models Based on Suboptimal Templates
In general, the accuracy of homology models is
observed to decrease with decreasing sequence similarity
between target and template.58 In the following, the
influence of inaccuracies of HM based on templates
sharing different degrees of sequence conservation is
assessed. For this, protein structures from the retroviral
protease subfamily, which contains eight members
(including HIV-1), were selected as templates to build
HMs of HIV-I protease.
The structures selected were (a) Simian Immunodefi-
ciency Virus protease (1SIP, 2.3 A˚ resolution) sharing
51% sequence identity,46 (b) HIV-2 protease (1IDA, 1.7 A˚
resolution) sharing 48% sequence identity,47 (c) Rous
Sarcoma Virus Protease (1BAI, 2.4 A˚ resolution) sharing
43% sequence identity,48 (d) equine infectious anemia vi-
rus protease (1FMB, 1.8 A˚ resolution) sharing 32%
sequence identity,49 and (e) Feline Immunodeficiency Vi-
rus (3FIV, 1.85 A˚ resolution) sharing 32% sequence iden-
tity with HIV-I protease.50
Models were built using SWISS-MODEL as described
earlier. The overall RMSD of the backbone atoms
between the models and the reference protein 1HVI is
1.02 A˚ for the model based on 1SIP (51% ID), 0.83 A˚ for
the model based on 1IDA (48% ID), 1.18 A˚ for the model
based on 1BAI (43% ID), 1.14 A˚ for the model based on
1FMB (32% ID), and 1.28 A˚ for the model based on 3FIV
(32% ID). If only residues within 5 A˚ of the ligand are
considered, the corresponding RMSD values are 1.53,
0.69, 1.63, 1.30, and 0.94 A˚, respectively. No suitable di-
meric X-ray structures that could serve as a template
are available for the Myeloblastosis-associated viral pro-
tease and the Mason-Pfizer monkey virus.
Figure 7(B–F) show the correlation between the exper-
imentally determined binding free energies and the cal-
culated values for the five homology models. For the
model based on Simian Immunodeficiency Virus prote-
ase (1SIP) the correlation is 0.84  0.02 (0.68  0.04),
for the model based on HIV-2 protease (1IDA) the corre-
lation is 0.81  0.02 (0.76  0.02), for the model based
on Rous Sarcoma Virus Protease (1BAI) it is 0.85  0.02
Fig. 8. The difference in total energy contribution (DDG) between the ref-
erence structure 1HVI and the suboptimal rotamer model for residues
within 5 A˚ of ligands A79285, L738317, and SB203238. The x-axis repre-
sents the residues of each of the monomer that fall within 5 A˚ of the
ligands and y-axis is the difference in total energy contribution in kcal/mol.
TABLE V. Calculated Binding Free Energies of the Ligands A79285, L738317, and
SB203238 for Both the Reference Structure 1HVI and the Suboptimal Rotamer Model
Ligand VDW Elec. Elec. desolv. Nonpolar desolv. Total
Reference protein (1HVI)
A79285 80.01 81.85 93.97 9.15 77.02
L738317 64.05 50.60 74.03 8.23 48.85
SB203238 59.22 40.47 67.44 8.23 40.48
Suboptimal rotamer model
A79285 73.67 58.61 76.81 9.01 64.49
L738317 67.55 62.81 69.16 7.93 69.13
SB203238 66.03 39.72 65.43 8.15 48.47
Energies are in kcal/mol.
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(0.79  0.03), for the model based on equine infectious
anemia virus protease (1FMB) the correlation is 0.87 
0.02 (0.81  0.04), and using Feline Immunodeficiency
Virus (3FIV) as a template a correlation of 0.88  0.02
(0.85  0.02) is obtained. It is interesting to note that
even with a HM based on a template sharing only 32%
sequence identity, a satisfactory correlation is obtained
and that there is virtually no difference between the cor-
relation obtained with a model based on a template with
51% sequence identity and one based on a template with
32% sequence identity. This observation might be spe-
cific for the aspartic proteases, and further protein fami-
lies will have to be studied to draw more general conclu-
sions.
CONCLUSIONS
In this work, a method for estimating the relative
binding free energy between ligand and protein of the
HIV-I protease system was validated and applied to esti-
mate DG between systematically perturbed protein
structures and a set of ligands. The method is based on
the MM-GBSA approach with docking of different
ligands into the same protein structure. Docking into
the same protein X-ray structure gave correlation coeffi-
cients between 0.78 and 0.85 including all 16 ligands
and 0.90 to 0.93 omitting the two outliers (A78791 and
KNI272) already found in a previous study.7 To put the
present results into perspective, it is instructive to com-
pare these correlation coefficients with correlations from
previous work. In a recent study of five peptidic inhibi-
tors, the correlation coefficient was R ¼ 0.89.57 A study
which investigated the influence of water molecules to
the ranking of ligands found correlation coefficients
between 0.30 and 0.61 for calculations without and with
water, respectively.59 Finally, a study of seven different
ligands gave a correlation coefficient of 0.89.60 Thus, the
present results are well within previous attempts to
describe ligand-binding in HIV-I.
Previously, MM-GBSA using the GB-MV2 model has
been validated compared with results from solving the
Poisson equation in estimating the total solvation energy
changes in insulin dimerization.35 Since MM-GBSA is a
relatively rapid method (scoring of one structure takes
20 s), it can be applied to assess the influence of varia-
tions in protein structures on the computation of ligand
affinities. The analysis of protein structures with differ-
ent cocrystallized ligands and homology models of differ-
ent accuracy shows that MM-GBSA is a useful tool to
assess the influence of modeling inaccuracies in compu-
tational drug design. Previously, it has been postulated
that HM down to 50% sequence identity between target
and template can be used in drug design.61,62 However,
in the case of the HIV-I protease system studied in this
work, it was shown that even models based on much
lower sequence identity can provide quite reliable
results (correlation of 0.85), while other factors (such as
the computational methods used for modeling side
chains) can have a much more detrimental effect. The
rapid and accurate method to calculate relative binding
free energies between ligands presented in this work
will allow analyzing the effects of inaccuracies of homol-
ogy models by systematically introducing errors which
are typically observed during homology modeling. These
results will provide the basis to specifically improve the
accuracy of homology modeling methods targeted for
applications in structure-based drug discovery.
In the present work, MM-GBSA was validated for
application to estimating ligand binding energies in pro-
tein structures and structures derived from homology
models, the target system HIV-I was used because it
represents a particularly well-tested and experimentally
well-characterized system. The method has been applied
to increasingly difficult docking problems. First, the
method was validated for 16 ligands in their own protein
structures and in two reference structures (1HVI,
1OHR). Fourteen out of the 16 ligands were found to
correlate favorably compared with the experimental
data. As a next level of complexity, ligand-binding ener-
gies were estimated for comparative models for HIV-I
protease built based on alignments to other retroviral
protease structures (SIV, HIV-2, RSV, EIAV, FIV) belong-
ing to the same subclass. Finally, the most challenging
application was to calculate ligand affinities for subopti-
mal side-chain conformations. It was shown that the
modeling of the side chains is crucial for ligand-binding
studies based on homology models for HIV-I protease.
Because this investigation showed that MM-GBSA is
a useful level to rank ligands, it should be possible to
apply this methodology to cases where the amount of ex-
perimental data is smaller and templates for the homol-
ogy models structurally more diverse. Work on less
favorable cases is under way.
REFERENCES
1. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B,
Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin
MJ, Natale DA, O’Donovan C, Redaschi N, Yeh LL. Uniprot: the
universal protein knowledgebase. Nucleic Acids Res 2004;32:
115–119.
2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weis-
sig H, Shindyalov IN, Bourne PE. The protein data bank.
Nucleic Acids Res 2000;28:235–242.
3. Blundell TL, Sibanda B, Sternberg MJ, Thornton JM. Knowl-
edge-based prediction of protein structures and the design of
novel molecules. Nature 1987;326:347–352.
4. Chothia C, Lesk AM. The relation between the divergence of
sequence and structure in proteins. EMBO J 1986;5:823–826.
5. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major
success of structure-assisted drug design. Ann Rev Biophys Bio-
mol Struct 1998;27:249–284.
6. Pearl LH, Taylor WR. A structural model for the retroviral pro-
teases. Nature 1987;329:351–354.
7. Zoete V, Michielin O, Karplus M. Protein-ligand binding free
energy estimation using molecular mechanics and continuum
electrostatics. Application to HIV-1 protease inhibitors. J Com-
put Aided Mol Des 2003;17:861–880.
8. Gohlke H, Kiel C, Case DA. Insights into protein-protein bind-
ing by binding free energy calculation and free energy decompo-
sition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol
2003;330:891–913.
9. Tame JRH. Scoring functions: a view from the bench. J Comput
Aided Mol Des 1999;13:99–108.
418 H.B. THORSTEINSDOTTIR ET AL.
PROTEINS: Structure, Function, and Bioinformatics DOI 10.1002/prot
5 Results
58
10. Ajay, Murcko MA. Computational methods to predict binding
free energy in ligand-receptor complexes. J Med Chem 1995;38:
4953–4967.
11. Hosur MV, Bhat TN, Kempf DJ, Baldwin ET, Liu B, Gulnik S,
Wideburg NE, Norbeck DW, Appelt K, Erickson JW. Influence
of stereochemistry on activity and binding modes for C2 symme-
try-based diol inhibitors of HIV-1 protease. J Am Chem Soc
1994;116:847–855.
12. Silva AM, Cachau RE, Sham HL, Erickson JW. Inhibition and
catalytic mechanism of HIV-1 aspartic protease. J Mol Biol 1996;
255:321–346.
13. Kaldor SW, Kalish VJ, Davies JF, II, Shetty BV, Fritz JE,
Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson
DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehu-
sen PP, Muesing MA, Patrick AK, Reich SH, Su KS, Tatlock JH.
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioa-
vailable inhibitor of HIV-1 protease. J Med Chem 1997;40:3979–
3985.
14. Backbro K, Lowgren S, Osterlund K, Atepo J, Unge T, Hulten J,
Bonham NM, Schaal W, Karlen A, Hallberg A. Unexpected
binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J
Med Chem 1997;40:898–902.
15. Jhoti H, Singh OM, Weir MP, Cooke R, Murray-Rust P, Wona-
cott A. X-ray crystallographic studies of a series of penicillin-
derived asymmetric inhibitors of HIV-1 protease. Biochemistry
1994;33:8417–8427.
16. Baldwin E, Bhat TN, Gulnik S, Liu B, Topol IA, Kiso Y, Mimoto
T, Mitsuya H, Erickson J. Structure of HIV-1 protease with
KNI-272, a tight-binding transition-state analog containing allo-
phenylnorstatine. Structure 1995;3:581–590.
17. Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA,
Kuo LC. Crystal structure at 1.9 A˚ resolution of human immunode-
ficiency virus (HIV) II protease complexed with L-735,524, an orally
bioavailable inhibitor of the HIV proteases. J Biol Chem 1994;
269:26344–26348.
18. Munshi S, Chen Z, Li Y, Olsen DB, Fraley ME, Hungate RW,
Kuo LC. Rapid X-ray diffraction analysis of HIV-1 protease-in-
hibitor complexes: inhibitor exchange in single crystals of the
bound enzyme. Acta Crystallogr Sect D 1998;54:1053–1060.
19. Hoog SS, Zhao B, Winborne E, Fisher S, Green DW, DesJarlais
RL, Newlander KA, Callahan JF, Moore ML, Huffman WF,
Abdel-Meguid SS. A check on rational drug design: crystal struc-
ture of a complex of human immunodeficiency virus type 1 prote-
ase with a novel g-turn mimetic inhibitor. J Med Chem 1995;38:
3246–3252.
20. Abdel-Meguid SS, Zhao B, Murthy KH, Winborne E, Choi JK, Des-
Jarlais RL, Minnich MD, Culp JS, Debouck C, Tomaszek TA, Jr,
Meek TD, Dreyer GB. Inhibition of human immunodeficiency virus-
1 protease by a C2-symmetric phosphinate. Synthesis and crystallo-
graphic analysis. Biochemistry 1993;32:7972–7980.
21. Thompson SK, Murthy KH, Zhao B, Winborne E, Green DW,
Fisher SM, DesJarlais RL, Tomaszek TA, Jr, Meek TD, Gleason
JG, Abdel-Meguid SS. Rational design, synthesis, and crystallo-
graphic analysis of a hydroxyethylene-based HIV-1 protease in-
hibitor containing a heterocyclic P10–P20 amide bond isostere. J
Med Chem 1994;37:3100–3107.
22. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD,
Navia MA. Crystal structure of HIV-1 protease in complex with
VX-478, a potent and orally bioavailable inhibitor of the
enzyme. J Am Chem Soc 1995;117:1181,1182.
23. Zoete V, Michielin O, Karplus M. Relation between sequence
and structure of HIV-1 protease inhibitor complexes: a model sys-
tem for the analysis of protein flexibility. J Mol Biol 2002;315:
21–52.
24. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan
S, Karplus M. CHARMM: a program for macromolecular energy,
minimization and dynamics calculations. J Comput Chem 1983;4:
187–217.
25. MacKerell AD, Jr, Bashford D, Bellott M, Dunbrack RL, Jr,
Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-
McCarthy D, Kuchnir L, Kuczera K, Lau TK, Mattos C,
Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, III,
Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe
M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empiri-
cal potential for molecular modeling and dynamics studies of
proteins. J Phys Chem B 1998;102:3586–3616.
26. Harte WE, Beveridge DL. Mechanism for the destabilization of
the dimer interface in a mutant HIV-1 protease - a molecular-
dynamics study. J Am Chem Soc 1993;115:1231–1234.
27. Miller M, Geller M, Gribskov M, Kent SB. Analysis of the struc-
ture of chemically synthesized HIV-1 protease complexed with a
hexapeptide inhibitor. Part 1: crystallographic refinement of 2 A˚
data. Proteins 1997;27:184–194.
28. Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ,
Kaufman JD, Kiso Y, Torchia DA. Solution NMR evidence that
the HIV-1 protease catalytic aspartyl groups have different ioni-
zation states in the complex formed with the asymmetric drug
KNI-272. Biochemistry 1996;35:9945–9950.
29. Brooks CL, III, Brunger A, Karplus M. Active site dynamics in
protein molecules: a stochastic boundary molecular-dynamics
approach. Biopolymers 1985;24:843–865.
30. Brooks CL, III, Karplus M. Solvent effects on protein motion and
protein effects on solvent motion. J Mol Biol 1989;208:159–181.
31. Lee MS, Salsbury FR, Jr, Brooks CL, III. Novel generalized
Born methods. J Chem Phys 2002;116:10606–10614.
32. Lee MS, Feig M, Salsbury FR, Jr, Brooks CL, III. New analyti-
cal approximation to the standard molecular volume definition
and its application to generalized born calculations. J Comput
Chem 2003;24:1348–1356.
33. Srinivasan J, Cheatham TE, III, Cieplak P, Kollman PA, Case
DA. Continuum solvent studies of the stability of DNA, RNA,
and phosphoramidate-DNA helices. J Am Chem Soc 1998;120:
9401–9409.
34. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee
M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J,
Case DA, Cheatham TE, III. Calculating structures and free
energies of complex molecules: combining molecular mechanics
and continuum models. Acc Chem Res 2000;33:889–897.
35. Zoete V, Meuwly M, Karplus M. Study of the insulin dimeriza-
tion: binding free energy calculations and per-residue free
energy decomposition. Proteins 2005;61:79–93.
36. Hermann RB. Theory of hydrophobic bonding. II. correlation of
hydrocarbon solubility in water with solvent cavity surface area.
J Phys Chem 1972;76:2754–2759.
37. Hasel W, Hendrikson TF, Still WC. A rapid approximation to
the solvent accessible surface areas of atoms. Tetrahedron Com-
put Methodol 1988;1:103–116.
38. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalyti-
cal treatment of solvation for molecular mechanics and dynam-
ics. J Am Chem Soc 1990;112:6127–6129.
39. McQuarrie DA. Statistical mechanics. New York: Harper and
Row; 1976.
40. Tidor B, Karplus M. The contribution of vibrational entropy to
molecular association. J Mol Biol 1994;238:405–414.
41. Rost B. Twilight zone of protein sequence alignments. Protein
Eng 1999;12:85–94.
42. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an
automated protein homology-modeling server. Nucleic Acids Res
2003;31:3381–3385.
43. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL
workspace: a web-based environment for protein structure
homology modelling. Bioinformatics 2006;22:195–201.
44. Johnson M, Srinivasan N, Sowdhamini R, Blundell T. Knowl-
edge-based protein modeling. Crit Rev Biochem Mol Biol 1994;
29:1–68.
45. Sali A, Blundell TL. Comparative protein modelling by satisfac-
tion of spatial restraints. J Mol Biol 1993;234:779–815.
46. Wilderspin A, Sugrue RJ. Alternative native flap conformation
revealed by 2.3 A˚ resolution structure of SIV proteinase. J Mol
Biol 1993;239:97–103.
47. Tong L, Pav S, Mui S, Lamarre D, Yoakim C, Beaulieu P,
Anderson PC. Crystal structures of HIV-2 protease in complex
with inhibitors containing the hydroxyethylamine dipeptide iso-
stere. Structure 1995;3:33–40.
48. Wu J, Adomat JM, Ridky TW, Louis JM, Leis J, Harrison RW,
Weber IT. Structural basis for specificity of retroviral proteases.
Biochemistry 1998;37:4518–4526.
49. Gustchina A, Kervinen J, Powell DJ, Zdanov A, Kay J, Wlo-
dawer A. Structure of equine infectious anemia virus proteinase
complexed with an inhibitor. Protein Sci 1996;5:1453–1465.
50. Laco GS, Schalk-Hihi C, Lubkowski J, Morrisa G, Zdanov A,
Olson A, Elder JH, Wlodawer A, Gustchina A. Crystal struc-
419STRUCTURE INACCURACIES IN LIGAND-BINDING
PROTEINS: Structure, Function, and Bioinformatics DOI 10.1002/prot
5.1 How Inaccuracies in Protein Structure Models Affect Estimates of Protein-Ligand
Interactions
59
tures of the inactive D30N mutant of feline immunodeficiency
virus protease complexed with a substrate and an inhibitor. Bio-
chemistry 1997;36:10696–10707.
51. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer:
an environment for comparative protein modelling. Electrophoresis
1997;18:2714–2723.
52. Laskowski RA, MacArthur MW, Moss D, Thornton JM. PRO-
CHECK: a program to check the stereochemical quality of pro-
tein structures. J Appl Crystallogr 1998;26:283–291.
53. Melo F, Feytmans E. Assessing protein structures with a non-
local atomic interaction energy. J Mol Biol 1998;277:1141–1152.
54. Canutescu AA, Shelenkov AA, Dunbrack RL, Jr. A graph-theory
algorithm for rapid protein side-chain prediction. Protein Sci
2003;12:2001–2014.
55. Bursulaya BD, Totrov M, Abagyan R, Brooks CL, III. Compara-
tive study of several algorithms for flexible ligand docking. J
Comput Aided Mol Des 2003;17:755–763.
56. Lepsik M, Kriz Z, Havlas Z. Efficienty of a second-generation
HIV-1 protease inhibitor studied by molecular dynamics and
absolute binding free energy calculations. Proteins 2004;57:279–
293.
57. Bartels C, Widmer A, Ehrhardt C. Absolute free energies of
binding of peptide analogs to the HIV-1 protease from molecular
dynamics simulations. J Comput Chem 2005;26:1294–1305.
58. Cozzetto D, Tramontano A. Relationship between multiple
sequence alignments and quality of protein comparative models.
Proteins 2005;58:151–157.
59. Fornabaio M, Spyrakis F, Mozzarelli A, Cozzini P, Abraham DJ,
Kellogg GE. Simple, intuitive calculations of free energy of bind-
ing for protein-ligand complexes. 3. The free energy contribution
of structural water molecules in HIV-1 protease complexes. J
Med Chem 2004;47:4507–4516.
60. Lee CY, Yang PK, Tzou WS, Hwang MJ. Estimates of relative
binding free energies for HIV protease inhibitors using different
levels of approximations. Protein Eng 1998;6:429–437.
61. Hillisch A, Pineda LF, Hilgenfeld R. Utility of homology models in
the drug discovery process. Drug Discov Today 2004;9:659–669.
62. Kopp J, Schwede T. Automated protein structure homology mod-
eling: a progress report. Pharmacogenomics 2004;4:405–416.
63. Verkhivker G, Appelt K, Freer ST, Villafranca JE. Empirical
free energy calculations of ligand-protein crystallographic com-
plexes. I. Knowledge-based ligand–protein interaction potentials
applie to the prediction of human immunodeficiency virus 1 pro-
tease binding affinity. Protein Eng 1995;8:677–691.
64. Bardi JS, Luque I, Freire E. Structure-based thermodynamic
analysis of HIV-1 protease inhibitors. Biochemistry 1997;36:
6588–6596.
65. Tawa GJ, Topol IA, Burt SK, Erickson JW. Calculation of rela-
tive binding free energies of peptidic inhibitors to HIV-1 prote-
ase and its I84V mutant. J Am Chem Soc 1998;120:8856–8863.
66. Kageyama S, Mimoto T, Murakawa Y, Nomizu M, Ford H Jr.,
Shirasaka T, Gulnik S, Erickson J, Takada K, Hayashi H, et al.
In vitro anti-human immunodeficiency virus (HIV) activities of
transition state mimetic HIV protease inhibitors containing allo-
phenylnorstatine. Antimicrob Agents Chemother 1993;37:810–
817.
APPENDIX
Analysis of the Ligand A78791
For A78791 a more detailed analysis can be carried
out, since binding free energies for the chemically simi-
lar ligands A76889, A76928, A77003, and A78791 are
available, which were determined by the same group
using identical protocols.11 All four ligands are C2 sym-
metry-based diol inhibitors, and A78791 is a deshydroxy
analogue of A77003. The main structural differences con-
cern the central portion of the ligands and primarily
affect the interactions with the active site pocket formed
by Asp25/250 and Gly27/27011; (see Fig. 1). Experimentally,
A78791 was found to be the best binder (16.2 kcal/mol,
Table II). Previous computational ligand binding studies
of all or some of the four ligands were based on empirical
free energy calculations,63 various approximations to the
binding free energy calculated from static structures and
MD simulations in implicit solvent,60 thermodynamic
computations of binding free energies,64 scoring of a se-
ries of protein–ligand complexes,59 and a combination of
molecular mechanics, dielectric continuum solvation, and
surface area based methods.65 The first two studies60,63
agree in that A78791 is the best inhibitor (although this
is not true for all approximate methods in Ref. 60).
Although the first study finds the other three ligands to
bind almost equally well (which is not in agreement with
experiment), the second study finds some differences
between them. The structure-based thermodynamic anal-
ysis finds A77003 to bind better than A78791 and
A76928.64 Unfortunately, Kellogg et al. do not report indi-
vidual binding free energies, while Erickson and co-
workers report data only on A77003.65
In the present calculations A76889, A76928, and
A77003 correlate well with the experimental values,
which are DG ¼ 14.2, 15.6, and 15.5 kcal/mol. The
binding mode of all four ligands is determined by how
well the ligand can optimize hydrogen bonding with
active site carboxylate groups and the van der Waals
contacts with the neighboring backbone atoms. In the X-
ray structures, the conformations of A77003 and A78791
are virtually identical. This suggests that any difference
in the binding free energy is not due to differences in
protein–inhibitor interactions.11 According to Hosur
et al., the presence of the second hydroxyl group on the-
ligand A77003 leads to larger desolvation energies and a
greater entropy loss upon binding relative to the A78791
analogue. These effects, together with the limited hydro-
gen-bonding compensation provided by the interaction
between Asp250 and the second hydroxyl group, are most
likely responsible for the decreased potency of A77003.11
Some of these proposals can be addressed by MD sim-
ulations. During the MD simulations in the reference
protein 1HVI, the four protein–ligand structures
(A76889, A76928, A77003, and A78791) superimpose on
average to within 0.15 A˚. To determine the possible rea-
sons why A78791 binds least strongly, DG is decomposed
into the electrostatic, van der Waals, nonpolar, and des-
olvation energy terms between the ligand and each resi-
due of the protein. Table AI shows each of these energy
terms for the residues Asp25/250 and Gly27/270 that pre-
viously have been determined to be the most important
for binding.11 Overall and in agreement with the above
proposition, Asp250 has a positive (destabilizing) contri-
bution to the binding free energy of A77003. However,
this contribution is even more destabilizing for A78791.
It was suggested that for A77003 the second hydroxyl
group (which is not present for A78791) leads to a larger
desolvation energy, which is not compensated for by
the Asp250 interaction to the hydroxyl group. Although
DGdesolv is larger for A77003 than for A78791 by 10 kcal/
mol (Asp250) and 5 kcal/mol (for the ligand), respectively,
in agreement with the proposition, the electrostatic
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TABLE AII. Per Residue Energy Decomposition for
the Residues Asp25/250 and Gly27/270 for the Four
Different Protonation States of Asp25/250 Indicated
by the /res/OD Code Which Gives the Residue and
Which One of the Oxygen Atoms Is Protonated
VDW Elec. Elec. desolv.
Nonpolar
desolv. Total
A78791/25/OD1
Asp25 0.52 1.13 0.74 0.05 0.95
Gly27 0.77 0.70 0.57 0.03 0.67
Asp250 0.50 7.00 12.21 0.06 4.84
Gly270 1.46 0.15 0.30 0.11 1.11
Ligand 38.99 29.95 39.67 6.63 35.91
A78791/25/OD2
Asp25 0.77 0.95 1.60 0.06 1.48
Gly27 0.71 0.49 1.07 0.02 1.31
Asp250 0.64 7.76 14.55 0.08 7.35
Gly270 1.24 0.24 0.39 0.08 1.47
Ligand 37.69 27.89 40.40 6.68 31.87
A78791/250/OD1
Asp25 0.87 9.49 13.92 0.05 5.25
Gly27 0.69 1.02 0.68 0.02 0.37
Asp250 0.96 0.65 0.25 0.06 0.62
Gly270 1.21 0.09 0.20 0.09 1.41
Ligand 39.04 29.48 40.65 6.68 34.55
A78791/250/OD2
Asp25 0.05 8.40 13.20 0.05 4.81
Gly27 0.82 1.12 0.22 0.03 0.05
Asp250 1.02 2.46 1.19 0.06 0.20
Gly270 0.84 0.57 0.92 0.02 2.35
Ligand 40.13 28.51 41.36 6.76 34.05
Energies are in kcal/mol.
TABLE AI. Per Residue Decomposition of the
Interaction Energy Between the Ligands
A76889, A76928, A77003, and A78791 and
Residues Asp25/250 and Gly27/270
VDW Elec. Elec. desolv.
Nonpolar
desolv. Total
A76889
Asp25 0.37 0.11 0.28 0.04 0.58
Gly27 0.87 0.46 1.50 0.01 1.92
Asp250 2.60 17.95 15.45 0.06 0.05
Gly270 0.90 0.66 0.07 0.06 0.37
Ligand 35.38 40.09 47.24 6.73 34.96
A76928
Asp25 0.45 0.94 0.66 0.06 0.79
Gly27 1.02 0.49 0.78 0.02 1.33
Asp250 2.17 18.07 17.85 0.08 1.88
Gly270 1.29 0.33 0.12 0.09 1.18
Ligand 38.93 39.03 44.56 6.89 40.30
A77003
Asp25 0.48 0.47 0.57 0.06 0.44
Gly27 1.42 0.65 0.86 0.14 1.35
Asp250 1.74 20.27 22.53 0.10 3.90
Gly270 0.70 0.13 1.25 0.02 1.85
Ligand 37.14 43.68 45.96 6.72 41.58
A78791
Asp25 0.83 0.70 1.18 0.04 1.35
Gly27 0.80 0.23 0.76 0.04 1.38
Asp250 0.48 7.40 12.34 0.05 5.38
Gly270 1.13 0.12 0.00 0.07 1.08
Ligand 39.18 28.83 40.43 6.70 34.27
Energies are in kcal/mol.
Fig. A1. Electrostatic interaction energy between the residues Asp25 and Asp250 of the reference protein
1HVI and the ligands A78791 (A,B) and A77003 (C,D), calculated for 500 frames (500 ps) along the trajec-
tory. Energies are in kcal/mol.
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Fig. A2. Hydrogen bonding network for the two configurations found for A77033 and Asp25/250 during the
MD simulation.
Fig. A3. Hydrogen bonding network for the three configurations found for A78791 and Asp25/250 during
the MD simulation.
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interaction between A78791 and Asp250 does not com-
pensate for this. One possibility is that the protonation
state of Asp25/Asp250 depends on the ligand. To exclude
this possibility, DG for A78791 has been calculated from
500 ps MD simulations for each of the four possible pro-
tonation states. Table AII shows the results for each of
the energy terms for the four possible protonation states
for residues Asp25/250 and Gly27/270. The initially cho-
sen protonation state of OD1 of Asp25 gives the best
overall binding free energies, supporting the choice of
this protonation state. Finally, it is possible to follow the
electrostatic interaction, Eelec, between the two ligands
and residues Asp25/Asp250 and Gly27/Gly270.
Figure A1(A) shows Eelec between Asp25 of the protein
and the ligand A77003 for 500 frames along the trajectory.
Eelec increases from around 3.5 kcal/mol to 0.5 kcal/mol
for most of the trajectory. This is related to a structural
change which removes the hydrogen bond between Asp25
and the ligand [Fig. A2(B)]. On the other hand, Figure
A1(B) shows that Eelec between Asp25
0 and A77003 is
slowly decreasing (with an average around 20 kcal/mol).
Towards the end of the trajectory, there are three hydro-
gen bonds between Asp250 and the ligand, one more than
at the beginning. Figure A2 shows snapshots of the struc-
tures for the two Asp residues and the ligand taken from
frames of the trajectory that represent each of the energy
states visited in Figure A1(A,B).
A similar analysis for A78791 shows that during the
MD simulations, the hydrogen bond between the ligand
and Asp25 is lost [see Fig. A1(C)], while Asp250 has only
one hydrogen bond with the ligand throughout the simula-
tion [Fig. A1(D)]. Figure A3 shows snapshots of the active
site taken from frames of the trajectory that represent
each of the three energy states visited in Figure A1(C,D).
In addition, hydrogen bonding between Asp25 and Asp250
is observed. This explains, in part, why A78791 is a less
favorable binder than A77003. Hydrogen bonding between
ligand and protein is in competition with H-bond forma-
tion between protein residues. For A78791, Asp250 is not
able to form as many and strong hydrogen bonds to the
ligand as A77003, and the desolvation energy does not
compensate for that. Systematic errors in the simulations
are unlikely, since the same two ligands (A78791 and
KNI272 for which no detailed analysis was made) are out-
liers based on independent simulations and on different
evaluation schemes for the binding free energies (LIE-like
method and MM-GBSA).
In their MD simulations, Hwang et al. kept the protein
frozen which will not lead to the possible complications
observed here. The only other simulation where MD simu-
lations were analyzed found A78791 to favor A77003 by
0.23 kcal/mol compared with 0.68 kcal/mol from experi-
ment.7 Finally, it is worthwhile to note that inhibition con-
stants were measured at pH 4.7, which is different from
the computations. In summary, conformational changes
during the MD simulations could contribute to the finding
that A78791 is not the best ligand as observed in the
experiment. The same applies to ligand KNI272 for which
a similar, but less detailed analysis showed that after 750
ps of MD simulation (see Fig. 6), the H-bonding pattern
between the ligand–hydroxyl group and the aspartic acid
residues surrounding the active site changed. This leads
to a decreased electrostatic interaction between the
ligand and the protein, which lowers the calculated
DG and gives a lower affinity than that found in the
experiment. The results on KNI272 were determined in
an independent study, using the same protocol as for
A76889, A76928, A77003, and A78791.66 In conclusion,
the more detailed simulations for the two outliers sug-
gest that the computational approach chosen is likely
not responsible for the disagreement between the
experiment and simulation.
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Applications
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One of the main obstacles in the routine application of molecular dynamics simula-
tions to virtual screening or structure-based drug design is the long calculation time
that is required and therefore computational biology is often limited by the available
computational resources. The work presented here aims to reduce the time that is
needed for a single molecular dynamics simulation by developing a method to run
multiple short molecular dynamic simulations on a PC Grid. This methodology is
first validated with the protein system used previously (HIV-1 protease) and then ap-
plied to a ligand docking study. There we want to answer the question if the docking
algorithms really score the lowest energy poses accurately and if molecular dynamics
approaches can help to improve both the pose from the docking program and to ob-
tain more accurate binding free energies for better ranking of the poses. This is then
applied to the estrogen rdeceptor β.
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1 Introduction
Proteins play an essential role in the lifecycle of cells. Of particular interest to
drug discovery are the many diseases that are a result of a faulty recognition of a
ligand or a specific pathway. These proteins could be inhibited by designing an
inhibitor that blocks an essential part of that pathway.
Virtual screening is commonly used to identify novel drugs that can be used
to fight diseases, often very successfully [1]. However, in order to give valuable
information these virtual screening algorithms have to dock potential ligands in
a correct pose and accurately score a very large number of compounds. This
means that for sake of efficiency that these scoring functions only address a single
pose and do not take any sampling into account. In addition the scoring functions
contain many approximations and therefore are limited in their accuracy [2]. This
can result in non-optimal pose selection and unrealistic energies.
An alternative would be to use more accurate scoring functions to evaluate
the binding energies and thereby eliminate those poses that are obviously ener-
getically incorrect. The most precise methods are so-called free energy methods,
such as free energy perturbation or thermodynamic integration [3], but they are
far too time consuming to be used for a high-throughput analysis of different lig-
ands. The MM-GBSA approach is commonly used to simulate protein-ligand in-
teractions [5] and has previously been applied successfully to estimate the relative
binding free energies of 16 ligands of the HIV-1 protease and to investigate the
influence of possible inaccuracies that can arise during homology modeling [4].
Although the MM-GBSA method offers quite fast computation, the total compu-
tation time needed for a single ligand binding study is still a bottleneck. In par-
ticular, the excessive calculation time for sampling conformations prevents any
large scale investigation, such as virtual screening. Traditionally, MD simulations
are run as a single continuous trajectory of relatively long timescales (nanosecond
scale), requiring excessive CPU time. In the approach presented here, we want
to reduce the time needed for computation by splitting up the MD simulation into
smaller units which then can be calculated simultaneously and independent from
each other on a distributed GRID of desktop PCs.
The idea of running multiple molecular simulations for increased sampling
is not new. Caves et al looked at the differences in sampling between running
an individual trajectory of 5 ns or ten independent trajectories of 120 ps each,
which only differ in the initial velocities. They found that the overall sampling
was improved by using the multiple independent trajectory approach and suggest
that it should be used to obtain better sampling [6]. Using the same approach
Loccisano et al looked at the A1−> A1,3 transition in MbCO. They found that by
running ten 400 ps simulations they were able to observe this transition frequently,
while using two 1.2 ns simulations they were only able to observe it once. The
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initial structures came from five x-ray structures with random initial velocities
[7]. Many other attempts have shown the improved sampling by running multiple
molecular simulations, especially to observe the conformational space of small
peptides and proteins [8,9]. All of these multiple molecular dynamics simulations
still have rather long timescales of at least 100 ps and often even on a nanosecond
scale and so far not much has been done to speed up conformational sampling for
protein-ligand binding studies.
In this work we first validate the multiple short trajectory approach by applying
it to the previously validated HIV-1 protease [4] at two different temperatures to
see if increasing the temperature results in increased sampling. Then we apply the
methodology to docked poses of the 16 ligands firstly to see if the overall pose
can be improved by running a molecular dynamics simulation on it, and secondly
to see if the scoring can be improved by employing a more advanced scoring
function. This methodology is then applied to a different protein system, i.e. the
estrogen receptor in order to see if the method is transferable to other systems.
2 Theoretical Methods
The theoretical methods used here are all described in chapter 5.
3 Results
Accurate calculation of protein-ligand binding energies is an essential part of the
drug discovery process. Unfortunately, the docking algorithms and subsequent
scoring functions need to make numerous approximations in order to screen a
large number of compounds on a reasonable time scale. Molecular dynamics sim-
ulations could potentially improve the ligand poses and provide sufficient sam-
pling to obtain more accurate binding energies using scoring functions such as
MM-GBSA. These calculations are however still too computationally demanding
to be of much use for large scale calculations. An additional limitation to molecu-
lar dynamics approaches is the need for a reliable set of parameters for the ligands
under investigation, since manually parameterizing the ligands is a difficult and
time consuming process.
In this work a new approach to rapidly perform molecular dynamics simula-
tions on a PC Grid is proposed. The aim is that this short simulation approach
(multiple short trajectory approach) will give comparable results to running a sin-
gle continuous trajectory (standard long trajectory approach) but in a shorter time.
This method is validated using the HIV-1 protease and a set of 16 ligands that
previously has been validated for the MM-GBSA approach. Additionally, we val-
3
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idate the automated parameterizing of Antechamber [12] for molecular dynamics
simulations. This method is then applied to docked poses of these 16 ligands and
finally to the estrogen receptor.
3.1 HIV-1 Protease
3.1.1 Validation of Short Molecular Dynamics Simulation approach
The standard approach of running molecular dynamics simulations for conforma-
tional sampling of protein-ligand interactions is to run a single continuous trajec-
tory of a relatively long time scale. In our approach we aim to shorten the com-
putation time needed by running independent multiple short molecular dynamics
simulations which are then suitable to be calculated on a distributed GRID of PC
computers. By this we hope both to shorten the overall computation time needed
and secondly to obtain comparable or even improved correlation to the experimen-
tal binding free energies, compared to using the standard long molecular dynamics
approach.
The multiple short trajectory approach was validated by correlation to exper-
imental energies. Molecular simulations of both the standard long and multiple
short approaches were first run at 300 K and in addition, both approaches were
run at 500 K to test if increased conformational sampling could be obtained with
increased temperature. For the short molecular dynamics simulation approach,
the increased temperature was only used for the 100 ps of the simulation used to
generate starting conformations, the actual short molecular dynamics simulation
of 10 ps each were performed at 300 K. Frames were extracted every 1 ps and the
binding energy over each trajectory was calculated.
Figure 1 shows the correlation coefficient between the calculated binding free
energy to the experimental binding free energy calculated every 100 ps of the total
simulation time of the short trajectory approach at 300 K (black line) and 500 K
(red line). Figure 1 A shows this for the complete set of ligands while 1 B excludes
the known outliers (A79785 and KNI272). The solid lines show the correlation
coefficient calculated for every 100 ps up to 1000 ps for the multiple short dynamic
approach, and the broken lines are the reference correlation coefficient calculated
for a standard long molecular dynamics simulation. The results show that the
multiple short trajectory approach is able to improve the correlation coefficient
to experimental binding free energies at both temperatures. Another interesting
observation is that for the multiple short molecular dynamics simulation at 300
K the correlation coefficient decreases from 0.86 to 0.84 until 600ps of simulated
time, but for the simulation at 500 K it increases from 0.76 to 0.83 until ca 500 ps
total simulation time.
Figure 2 shows the correlation graphs between the experimentally determined
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Figure 1: Correlation coefficient of calculated relative binding free energy (ex-
cluding the outliers) to the experimental binding free energies as a function of
simulated time for A , simulations including all ligands and B for simulations
excluding the two outliers (A79785 and KNI272) The solid lines show the corre-
lation coefficient calculated for every 100ps up to 1000ps for the multiple short
dynamic approach, and the broken lines are the reference correlation coefficient
calculated for a standard long molecular dynamics simulation
binding free energy and the calculated binding free energy at 300 K for 500 ps
of the standard long molecular dynamics simulation (A), 50x10ps of the multiple
short molecular dynamics simulation (B) and at 500 K for 500 ps of the standard
long molecular dynamics simulation (C), 50x10 ps of the multiple short molecu-
lar dynamics simulation (D) including all the ligands. At both temperatures the
multiple short molecular dynamics simulation approach is able to improve the cor-
relation coefficient between calculated binding energies and experimentally deter-
mined energies. Figure 3 shows the same excluding the two outliers and again the
same improvement of the correlation coefficient is observed.
The tables for the energy contributions for the molecular dynamics simula-
tions of each of the ligand for the standard long trajectory approach and the mul-
tiple short are in the supplementary material for both the simulations at 300 K
and 500 K. A general observation is that the total binding free energies are quite
similar between the standard long molecular dynamics approach and the multiple
short dynamics approach at 300 K. However, there are some energy differences
between the standard long molecular dynamics approach and the multiple short
dynamics approach at 500K and between simulations at 300 K and 500 K. For
example, the ligand A76889 has a total energy of -77.61 ± 6.75 for the standard
long simulation at 300 K, and a very similar value of -76.02 ± 6.92 for the multi-
5
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Figure 2: Correlation between the experimentally determined binding free energy
and the calculated one for all the ligands for standard long molecular dynamics
simulations and multiple short molecular dynamics simulations at 300 K (A, B)
and 500 K (C,D)
ple short simulation at the same temperature. For the standard long simulation at
500K it gets the considerably higher energy of -61.90 ± 8.49 and -69.98 ± 7.70
for the multiple short trajectory approach at the same temperature.
These results show that although the binding energy values differ between
different target temperatures, the multiple short molecular dynamics simulations
approach is able to obtain good correlation to experimental values. In some cases
this correlation is improved from what is obtained with the standard long trajec-
tory approach.
6
5 Results
70
Figure 3: Correlation between the experimentally determined binding free energy
and the calculated one excluding the outliers (A79785 and KNI272) for standard
long molecular dynamics simulations and multiple short molecular dynamics sim-
ulations at 300 K (A, B) and 500 K (C,D)
3.1.2 Validation of automatic parameterization
To validate the approach of using Antechamber to automatically parameterize lig-
ands for molecular dynamics with CHARMM, first the previously validated lig-
ands of the HIV-1 protease were re-parameterized with Antechamber. Figure 4
shows the experimental binding free energy vs. the calculated relative binding
free energy for the Antechamber parameterized ligands (A all 16 ligands, B with-
out the two outliers A79785 and KNI272). The correlation coefficient for the
complete dataset is 0.73 which is considerably lower than using previous manu-
ally parameterized parameters (0.83). But if the two known outliers are excluded
the correlation coefficient increases to 0.85, compared to 0.9 with the original pa-
rameters. Considering that this is a much faster method with a simpler force fields,
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these result are quite adequate. These results are very encouraging and promising
for the application of this automated parameterization for future work.
Figure 4: Correlation between the experimentally determined binding free energy
and the calculated one for multiple short molecular dynamics simulations for all
ligands (A) and excluding the outliers (A79785 and KNI272) (B).
3.1.3 Application to Docking
A Glide docking of the 16 ligands in the HIV-1 protease was performed using
Glide’s SP docking procedure. Since the HIV-1 protease ligands are quite large,
the number of rotatable bonds and atoms was increased from the standard values
to ensure that the ligands would be docked without any problems. Two docking
runs were set up, one for ligands that require a structural water to be present in the
protein, and one for the two ligands that require the absence of the structural water
(aha001 and aha006). The protonation state of the catalytic Asp residues was set
to be on OD1 of Asp25. The respective docking times were 162 minutes for the 14
ligands with water, and 5.4 minutes for the 2 ligands without the structural water.
Glide assigns a Emodel score for each of the docked poses and since we know
the position of the ligand in the crystal structure we can calculate the rmsd of the
docked pose to the reference structure. For each ligand a number of poses were
selected for further study. The pose with maximum and minimum rmsd to the
reference structure and the maximum and minimum Emodel score are selected
and in addition at equal intervals based on the rmsd values.
The poses that were selected were then submitted to a MM-GBSA calculation
on the PC-GRID. The docking results are all in the Supplementary material. It is
observed, that in general after molecular dynamics and evaluation of MM-GBSA
8
5 Results
72
the binding free energies are better. The trend towards obtaining good binding
energies for the low rmsd poses and worse energies for the high rmsd poses is
much more pronounced for the MM-GBSA approach than with only using Glide,
especially for the poses with rmsd values lower than 4 A˚. This is illustrated in
figure 5. There are some exceptions to this such as the ligand AHA006 where the
results are more or less random both in the case of MM-GBSA and Glide. The
ligand AHA001 is also an interesting case since it has two distinct populations,
up to a rmsd of 4 A˚, then there is a population at a rmsd of 6.5 A˚ that obtains very
good energies as seen in figure 6 . This will be analyzed in more detail in the next
section.
Figure 5: Docking results for the ligand A76889. The left panel shows the average
rmsd vs the average binding energy for MM-GBSA calculations. The right panel
shows the rmsd vs. the Emodel score for poses from Glide docking.
3.1.4 Analysis of results
For the analysis of the different trajectory approaches we fist look at the difference
between the energy sampling of the standard long and multiple short trajectories
of ligand A76889 at 300K and then the same for these at 500K, and finally if
the energy sampling between the multiple short trajectory approaches at 300K
and 500K are different. Then we perform a principle component analysis to see
if any conformational sampling differences can be identified in order to find im-
portant structural features. Finally, we have a look at two of the docked ligands
to see how they compare to reference calculations of the crystal pose of the ligand.
Analysis based on energy contribution
In order to investigate the contribution of residues to the binding free energy be-
tween the different approaches, cluster analysis based on per residue binding en-
9
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Figure 6: Docking results for the ligand AHA001. The left panel shows the av-
erage rmsd vs the average binding energy for MM-GBSA calculations. The right
panel shows the rmsd vs. the Emodel score for poses from Glide docking
ergy contributions. Figure 7 shows the results from the analysis. The left panel
shows the average energy contribution of the residues within 5A˚of the ligand and
the right panel shows the clusters obtained based on the energy metric. The size
of the cluster corresponds to the number of frames it contains, and the color de-
pends on the contributions from each of the approaches. For the first comparison
of the standard long trajectory approach and multiple short approach at 300 K the
average energy contribution of the residues is very similar with only residues 124
and 129 that show some differences (figure 7 (A)). This is reflected in the cluster-
ing, where the clusters are quite mixed in the contributions from each approach.
For the comparison of the standard long trajectory approach and multiple short
approach at 500 K (figure 7 (B)) the average energy contribution of the residues is
in general a bit lower for the multiple short trajectory approach (red circles) and
again there are only a couple of residues that show a big spread in the energies,
namely 124 and 128. The largest clusters are again quite mixed but a lot of the
smaller clusters are specific for either of the approaches. Finally for the compari-
son of the multiple short trajectory approaches at 300 K and 500 K (figure 7 (C))
from the average energy contribution it can be seen that some of the residues such
as 28, 124, 128 and 129 differ considerably in their energy values. The clustering
in this case is also distinguishing a bit more between the two approaches, but since
the overall energy differences aren’t that big they are quite mixed as well.
Analysis based on PCA
Figure 8 shows the results from a principle component analysis which was used
to highlight major difference in the motions of the dynamics approaches. For the
comparison of the standard long and multiple short trajectory approach for 300 K
figure 8(A) the plot shows that the multiple short trajectory approach only sam-
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ples a fraction of the standard long trajectory approach. The structural analysis
shows however that for the first principle component the conformational differ-
ences are very small. For the comparison of the standard long and multiple short
trajectory approach for 500 K figure 8(B) the plot shows a larger area is sampled,
and the multiple short trajectory approach again only samples a part of what the
standard long trajectory approach does. The structural analysis shows that there
are differences; Phe152 is very flexible in the standard long approach, and so
are the residues in the flap (Gly51/150), and the residues in the binding pocket
(Ala28/127 and Gly27/126) show some variation as well. Finally, we look at the
differences between the multiple short trajectory approach at 300 K and at 500
K ( figure 8(C)). Here, based on the plot of the first two principle components
the approaches seem to be sampling two separated areas. The structural analysis
confirms this finding, The side-chains of Met145 and Asp25 are oriented differ-
ently, and Gly126 shows a considerable backbone difference between the two
approaches.
Analysis of two docked ligands
First, we analyse a two of docked poses for the ligand A76889. Figure 9 shows the
results for the analysis. In figure 9(A) the plot of the average rmsd to the reference
ligand vs the average binding energy is shown and to the right the structures of a
few of the docked poses. Two of those were selected for further analysis, pose 19
which has the lowest rmsd and pose 3 which has the highest rmsd. Although pose
19 is overall structurally more similar, there are some large differences between
poses, in particular pose 3 is very different from the reference. These poses were
clustered in comparison to the MM-GBSA simulation of the reference structure.
Figure 9(B) shows that for both of the cases there is a complete separation be-
tween the clusters. This is to be expected since the energy difference is quite large
even for the pose with the lowest rmsd value (around 20 kcal/mol difference).
Figure 9(C) shows the average energy contribution of each residue within 5 A˚of
the ligand to the binding free energy. Here it can clearly be seen that only a few
residues are responsible for this large differences in the binding energy. The main
contributors to this difference are Asp124 and 128 and to a lesser extent residues
25, 28, 30 and 127.
Results for the ligand aha001 are shown in figure 10. In figure 10(A) the plot
of the average rmsd to the reference ligand vs the average binding energy is shown
and to the right the structures the two poses that were selected for further analysis.
Pose 59 shows considerable overall similarity, but pose 45 shows large structural
difference, mainly in the central part of the ligand. These poses were clustered in
comparison to the MM-GBSA simulation of the reference structure. In contrast
to the results for ligand a86889, the clustering for ligand aha001 shown in figure
10 (B) has no clear separation of the clusters, but still a tendency for either of the
approaches is observed. Figure 10(C) shows the average energy contribution of
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each residue within 5 A˚of the ligand to the binding free energy. Although pose 45
has a large rmsd against the crystal structure the calculated binding energy is very
favorable. This is due to improved energy contributions of residues 29 and 124,
while residues 25, 30, 50 128 and 129 stay mostly unchanges.
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Figure 7: Results of the clustering analysis based on the per residue binding en-
ery contribution for the standard long and multiple short trajectory approaches at
300 K and 500 K. The left panel shows the average energy contribution of the
residues within 5A˚of the ligand and the right panel shows the clusters obtained
by clustering based on the energy metric. The sizes of the clusters correspond to
the number of frames it contains and the color to the ratio between the different
approaches (red is fully populated by the long trajectory (A and B) or the short
trajectory approach at 300K (C).
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Figure 8: Principle component analysis of the standard long and multiple short
trajectory approaches at 300K and 500K. The left panel shows the plots for the
first two principle components and the right panel shows the extreme atomic dis-
placement of the first principle component (red for the long trajectory approach
and blue for the short trajectory approach, last panel blue for 300K and red for
500K)
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Figure 9: Docking results for the ligand A76889. (A) The left panel shows the
average rmsd vs the average binding energy for MM-GBSA calculations and the
right panel shows the rmsd vs the Emodel score for the poses from Glide docking.
(B) Shows the results from clustering based on per residue energy contributions
as compared to multiple short dynamics simulation the crystal pose of the ligand.
(C) Shows the average energy of residues between the poses compared and the
crystal structure pose.
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Figure 10: Docking results for the ligand AHA001. (A) The left panel shows the
average rmsd vs the average binding energy for MM-GBSA calculations and the
right panel shows the rmsd vs the Emodel score for the poses from Glide docking.
(B) Shows the results from clustering based on per residue energy contributions
as compared to multiple short dynamics simulation the crystal pose of the ligand.
(C) Shows the average energy of residues between the poses compared and the
crystal structure pose.
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3.2 Estrogen Receptor
Motivated by the good correlation obtained for the HIV-1 ligands, the Antecham-
ber parameterization approach was applied to 13 ligands of the estrogen receptor.
Figure 11 shows the chemical structure of these 13 ligands. The protein with
PDB entry 1XPC was selected as the reference structure in which all the other
ligands were docked. The pdbbind database (http://www.pdbbind.org) is a col-
lection of experimentally measured binding affinity data (Kd, Ki, and IC50) for
the protein-ligand complexes available in the Protein Data Bank (PDB) [11]. It
contains binding data for the estrogen receptor as shown in table 1.
Figure 11: Schematic overview of the estrogen receptor ligands used in this study
The protonation states of the histidine residues was taken from the paper of
Oostenbrink et al [30] and are shown in table 2
As previously done, the molecular dynamics simulations were performed at
two different temperatures to investigate whether increased temperature results in
better conformational sampling.
Table 7 and 8 in the supplementary material show the calculated energy terms
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Table 1: Binding data for the estrogen receptor from the pdbbind database, the
affinity as given in the pdbbind database, the affinity in kcal/mol, resolution of
the crystal structure and the root mean square deviation to the reference structure
selected (1XPC)
pdb entry Affinity (pKd) Affinity (kcal/mol) Resolution (A˚) RMSD to ref
2bj4 4.47 -6.10 2 0.49
2b1v 5.74 -7.83 1.8 0.50
1x7e 5.97 -8.14 2.8 0.57
2fai 6.24 -8.51 2.1 0.42
1gwr 6.60 -9.00 2.4 0.55
1gwq 7.12 -9.71 2.45 0.54
1xqc 7.20 -9.82 2.05 0.69
1uom 7.72 -10.53 2.28 0.51
1xpc 8.77 -11.96 1.6 0.00
1xp9 8.89 -12.12 1.8 0.27
1sj0 9.10 -12.41 1.9 0.29
1xp1 9.30 -12.68 1.8 0.19
1xp6 9.40 -12.82 1.7 0.17
for the multiple short simulations of the the 13 ligands of Estrogen receptor at 300
K and 500 K.
Figure 12 shows the correlation between the experimentally determined bind-
ing free energy and the calculated relative binding free energy, where the black
stars are binding free energies calculated from simulations at 300 K and the red
circles are the binding free energies calculated at 500 K. Figure 12 (A) shows the
correlation coefficients for the standard long molecular dynamics at 300 K and
500 K. The correlation coefficient is 0.71 at 300K which improves to 0.75 for the
simulation at 500 K. Figure 12 (B) shows the same improvement for high temper-
ature simulations for the multiple short simulations. The correlation coefficient is
a bit lower in this approach for the simulation at 300 K, or 0.68, but increases to
0.85 for the simulation at 500 K. There is one ligand (BJ4) that is an outlier in the
simulation but for the multiple short simulations it results in much lower binding
energies which gives a considerably better correlation coefficient to the experi-
mental values (especially at 500 K). Figures 12 (C) and 12 (D) show the same
graphs, but excluding this outlier. For the standard long simulation this increases
slightly the correlation coefficient to 0.86 at 300 K and 0.89 at 500 K (see fig 12
(C)). For the multiple short simulations this brings the correlation coefficient up
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Table 2: Protonation states of histidine residues in Estrogen Receptor. HSD means
that the delta oxygen is protonated, and HSE the epsilon oxygen.
356 373 377 398 474 476 488 501 513 516 524 547
Prot. state HSE HSD HSD HSD HSE HSD HSE HSD HSD HSE HSE HSE
to 0.85 for simulations at 300 K and to 0.90 for the simulations from 500 K (fig
12 (D)).
These results show that for the estrogen receptor a very good correlation can be
obtained to experimental values using the multiple short trajectory approach. This
corrlation is as good as with the standard long approach. Indeed, the correlation
coefficient of 0.85 is obtained for the multiple short trajectory approach at 300K
and can even be increased to 0.9 at 500K.
3.2.1 Application to Docking
A Glide docking was set up for these 12 ligands of the estrogen receptor using
the SP docking procedure. As before a number of poses for each ligand were
selected for further study. The pose with maximum and minimum rmsd to the
reference structure and the maximum and minimum Emodel score are selected
and in addition at equal intervals based on the rmsd values.
The poses that were selected were then submitted to a MM-GBSA calculation
on the PC-GRID. The docking results are all in the Supplementary material.
Compared to the HIV-1 protease there doesn’t seem to be any clear trend to-
wards better energies with lower rmsd for the estrogen receptor. The results are
rather random regardless of the method used to evaluate the energies. Figure 13
illustrates an example of this.
In this figure the poses that have a very low rmsd (∼ 2 A˚) have a very large
spread in their energy values, which cannot be improved with the MM-GBSA
approach.
4 Conclusions
Conclusions that can be drawn from this work are first of all that the multiple short
molecular dynamics approach is successful in reproducing results using the stan-
dard long trajectory approach of a single 500 ps molecular dynamics simulation.
Using the standard long approach a calculation of one ligand in the HIV-protease
takes up to 4 days to complete, in contrast for a single ligand in the HIV-1 protease
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Figure 12: Correlation between the experimentally determined binding free en-
ergy and the calculated one for multiple short molecular dynamics simulations.
the calculation using the multiple short trajectories takes only 48 hours. The most
time is spent on the pre-MD simulation, equilibrating the protein-ligand complex
and producing the starting coordinate and velocities for subsequent calculations
(24 hours). Thus, the multiple short trajectory approach allows a significant speed
up of the calculation and therefore is applicable to the computationally intensive
task of rescoring top docked poses.
This work demonstrates that the sampling of the energies of the HIV-1 pro-
tease is equal for both approaches. It is therefore hard to distinguish some pre-
ferred energy values or ranges that are more specific for either of them. In general
the residue Asp124 shows the largest variety, and in addition residues 28, 128 and
129 are responsible for most of the variation in the energy sampling between these
20
5 Results
84
Figure 13: Docking results for the ligand XP9. The left panel shows the average
rmsd vs the average binding energy for MM-GBSA calculations and the right
panel shows the rmsd vs the Emodel score for the poses from Glide docking.
approaches. From the principle component analysis it is observed that the actual
conformational difference between the standard long and multiple short trajectory
approach for 300 K is very small. It is slightly larger for the same sampling at 500
K and in comparing the multiple short trajectory approaches for 300K and 500 K
some structural changes can be observed. These are however not large enough to
have a large impact on the average energy of the protein-ligand binding.
For the docking of ligands in the HIV-1 protease the MM-GBSA approach is
able to distinguish nicely between good and bad poses from Glide docking as seen
from the general trend of high rmsd poses obtaining very bad energies from the
MM-GBSA calculations. There are exceptions from this, for example the ligand
aha001 where the highest rmsd pose also has one of the best binding free energies.
This is due to it’s ability to optimize exceptionally good energy contributions to
residues 124 and 128 in spite of a worse overall rmsd value for the pose.
In general it can be seen from this work that clustering is a nice tool to identify
residues contribution most to the binding free energy. There are only a handful of
residues that are deterministic of the binding free energy for a given ligand in the
HIV-1 protease. Once these are identified they could potentially be used to reduce
the sampling space needed for flexible docking and by that obtain a more reliable
pose from docking programs.
On the other hand, for the Estrogen Receptor we are not able to obtain such a
clear distinction between high rmsd poses and those with low rmsd.
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6 Supplementary Information
6.1 HIV-1 Protease
6.1.1 Binding Energy Estimation
Tables 3 - 6 show the energy contributions for the standard long and multiple short
trajectory approaches at 300K and 500K.
Table 3: Energy contributions for the standard long trajectory approach of HIV-1
protease at 300K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
a76889 -73.17 ± 4.13 -78.25 ± 6.51 82.85 ± 6.07 -9.04 ± 0.07 -77.61 ± 6.75
a76928 -79.22 ± 4.36 -72.43 ± 12.49 79.07 ± 6.18 -9.11 ± 0.11 -81.70 ± 9.78
a77003 -75.23 ± 3.99 -88.03 ± 7.09 93.06 ± 5.62 -9.02 ± 0.08 -79.22 ± 6.38
a78791 -77.17 ± 3.60 -60.38 ± 10.06 80.78 ± 7.27 -8.98 ± 0.08 -65.75 ± 7.10
a79285 -82.93 ± 3.93 -87.28 ± 9.91 97.50 ± 6.79 -9.07 ± 0.08 -81.78 ± 6.46
ag1343 -64.71 ± 3.47 -53.18 ± 5.88 63.97 ± 5.28 -7.67 ± 0.10 -61.59 ± 6.93
aha001 -56.09 ± 3.43 -54.11 ± 5.80 61.80 ± 5.89 -7.18 ± 0.10 -55.58 ± 6.32
aha006 -61.65 ± 3.22 -52.89 ± 4.29 67.30 ± 5.56 -7.48 ± 0.08 -54.73 ± 6.83
gr126045 -48.08 ± 3.66 -58.84 ± 5.56 68.52 ± 5.04 -6.67 ± 0.08 -45.07 ± 5.59
kni272 -68.06 ± 3.79 -68.95 ± 5.14 80.49 ± 5.62 -7.96 ± 0.09 -64.48 ± 6.92
l735524 -66.02 ± 3.47 -58.26 ± 5.60 72.43 ± 5.72 -8.24 ± 0.12 -60.09 ± 5.99
l738317 -62.84 ± 3.42 -67.74 ± 6.81 80.12 ± 6.26 -8.29 ± 0.11 -58.75 ± 7.68
sb203238 -60.96 ± 2.76 -36.69 ± 7.04 84.49 ± 8.76 -8.12 ± 0.11 -21.27 ± 8.93
sb204144 -67.81 ± 4.34 -64.68 ± 9.72 81.67 ± 6.58 -8.72 ± 0.15 -59.53 ± 8.60
sb206343 -62.32 ± 3.64 -69.04 ± 5.84 81.91 ± 6.64 -8.25 ± 0.11 -57.70 ± 7.55
vx478 -54.88 ± 3.45 -57.34 ± 5.84 63.78 ± 5.65 -7.00 ± 0.07 -55.44 ± 5.51
6.1.2 Application to docking
Figures 14 - 17 show the docking results for the 16 ligands of the HIV-1 proease.
Figures 14 - 17 show the results of the docking. The left panel shows the av-
erage rmsd to the reference structure vs the average binding energy value from
the MM-GBSA calculations and the right panel shows the rmsd to the reference
structure vs the Emoldel score for the poses docked with Glide. In figure 14 the
ligands are generally docked with not too high accuracy, it is only ligand A76928
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Table 4: Energy contributions for the multiple short trajectory approach of HIV-1
protease at 300K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
a76889 -74.36 ± 4.10 -76.44 ± 6.58 83.79 ± 6.72 -9.01 ± 0.08 -76.02 ± 6.92
a76928 -78.43 ± 4.44 -81.44 ± 6.68 88.42 ± 6.07 -9.14 ± 0.08 -80.59 ± 6.64
a77003 -75.30 ± 4.31 -89.01 ± 6.51 94.38 ± 5.56 -9.01 ± 0.08 -78.94 ± 6.93
a78791 -75.84 ± 4.28 -71.52 ± 5.77 85.45 ± 5.99 -9.01 ± 0.09 -70.92 ± 6.95
a79285 -83.05 ± 4.14 -86.00 ± 9.10 96.33 ± 6.78 -9.14 ± 0.09 -81.86 ± 6.60
ag1343 -65.42 ± 3.45 -51.22 ± 7.47 63.94 ± 5.26 -7.79 ± 0.09 -60.49 ± 7.32
aha001 -54.99 ± 3.18 -52.46 ± 5.90 62.78 ± 6.02 -7.25 ± 0.09 -51.92 ± 6.40
aha006 -60.33 ± 3.41 -51.53 ± 3.77 66.20 ± 5.16 -7.49 ± 0.08 -53.15 ± 5.55
gr126045 -49.76 ± 3.38 -61.23 ± 5.70 70.58 ± 5.29 -6.75 ± 0.11 -47.17 ± 6.01
kni272 -66.02 ± 3.49 -68.05 ± 5.91 82.56 ± 6.78 -7.98 ± 0.10 -59.50 ± 6.66
l735524 -65.48 ± 3.44 -54.86 ± 5.39 64.94 ± 5.02 -8.10 ± 0.11 -63.50 ± 5.99
l738317 -63.35 ± 3.42 -59.18 ± 6.08 78.36 ± 6.51 -8.35 ± 0.11 -52.53 ± 6.80
sb203238 -58.09 ± 3.66 -51.16 ± 7.63 93.41 ± 9.89 -8.20 ± 0.15 -24.03 ± 9.07
sb204144 -69.45 ± 4.02 -63.54 ± 7.60 83.12 ± 6.80 -8.86 ± 0.14 -58.74 ± 7.62
sb206343 -62.06 ± 3.75 -67.95 ± 6.00 82.10 ± 7.24 -8.32 ± 0.09 -56.24 ± 7.47
vx478 -55.05 ± 3.43 -56.02 ± 5.28 62.73 ± 5.82 -6.97 ± 0.08 -55.30 ± 5.89
that has one pose below 3A˚I˙n all of these cases the higher the rmsd gets, the
worse the energies become. For figure 15 the same is observed for A79285 and
AG1343. Ligand AHA001 shows the same trend up to 4 A˚but there is a small
cluster of poses with high rmsd values that get very good binding free energies.
The poses of ligand AHA006 are behaving very erratically and impossible to ex-
tract some general trend from those values. For the ligands in figure 16 the ligand
L738317 shows a trend of worse energies with higher rmsd values and to some
extent GR126045 shows the same, but the ligands KNI272 and L735524 behave
more randomly. Although in the case of ligand KNI272 the rmsd values are all
very high. Lastly for figure 17 the ligands SB203238 and SB204144 have only
high rmsd poses.
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Table 5: Energy contributions for the standard long trajectory approach of HIV-1
protease at 500K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
a76889 -69.78 ± 5.01 -65.65 ± 8.53 82.52 ± 7.44 -8.99 ± 0.11 -61.90 ± 8.49
a76928 -72.53 ± 4.98 -71.19 ± 11.94 84.53 ± 7.88 -9.06 ± 0.12 -68.24 ± 10.05
a77003 -70.54 ± 5.21 -82.35 ± 8.80 91.06 ± 8.28 -9.01 ± 0.13 -70.84 ± 9.77
a78791 -74.80 ± 4.93 -56.38 ± 7.31 77.68 ± 7.19 -8.96 ± 0.13 -62.45 ± 8.43
a79285 -76.22 ± 5.52 -83.26 ± 12.83 100.40 ± 10.93 -9.15 ± 0.12 -68.22 ± 9.32
ag1343 -61.88 ± 4.54 -47.81 ± 9.00 63.62 ± 6.96 -7.66 ± 0.13 -53.73 ± 8.05
aha001 -52.86 ± 4.42 -43.95 ± 8.30 58.34 ± 7.34 -7.20 ± 0.12 -45.67 ± 8.40
aha006 -60.98 ± 4.62 -48.66 ± 5.72 63.64 ± 6.89 -7.50 ± 0.10 -53.51 ± 7.11
gr126045 -46.93 ± 4.48 -46.93 ± 8.52 61.83 ± 7.38 -6.67 ± 0.14 -38.70 ± 7.23
kni272 -64.14 ± 4.52 -58.63 ± 8.13 80.77 ± 6.91 -7.83 ± 0.14 -49.82 ± 8.04
l735524 -62.32 ± 4.96 -56.32 ± 9.69 64.40 ± 7.15 -8.25 ± 0.16 -62.49 ± 7.94
l738317 -59.49 ± 4.69 -57.58 ± 11.12 73.22 ± 7.73 -8.22 ± 0.18 -52.08 ± 10.66
sb203238 -58.51 ± 4.13 -36.38 ± 8.02 70.10 ± 8.44 -8.03 ± 0.15 -32.82 ± 9.57
sb204144 -66.37 ± 5.32 -53.46 ± 9.27 77.50 ± 6.93 -8.85 ± 0.19 -51.18 ± 9.18
sb206343 -59.09 ± 5.17 -61.68 ± 8.11 79.52 ± 9.27 -8.21 ± 0.17 -49.46 ± 10.42
vx478 -53.98 ± 3.98 -44.84 ± 6.38 59.52 ± 6.35 -7.00 ± 0.11 -46.31 ± 7.08
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Table 6: Energy contributions for the multiple short trajectory approach of HIV-1
protease at 500K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
a76889 -72.75 ± 4.29 -69.68 ± 6.35 81.47 ± 6.51 -9.02 ± 0.10 -69.98 ± 7.70
a76928 -75.64 ± 4.54 -69.10 ± 8.68 79.06 ± 7.00 -9.12 ± 0.11 -74.80 ± 8.35
a77003 -72.24 ± 4.79 -83.83 ± 7.39 91.36 ± 8.00 -9.00 ± 0.12 -73.71 ± 8.75
a78791 -77.53 ± 4.43 -58.52 ± 5.93 76.69 ± 6.43 -9.03 ± 0.11 -68.40 ± 7.67
a79285 -80.47 ± 4.99 -82.29 ± 9.85 96.36 ± 8.14 -9.22 ± 0.12 -75.62 ± 8.16
ag1343 -61.36 ± 4.10 -54.59 ± 5.98 67.15 ± 6.61 -7.81 ± 0.13 -56.60 ± 7.40
aha001 -54.40 ± 3.73 -47.35 ± 5.78 58.95 ± 5.83 -7.33 ± 0.14 -50.14 ± 7.01
aha006 -61.11 ± 3.57 -50.11 ± 4.89 66.62 ± 5.63 -7.43 ± 0.10 -52.03 ± 6.91
gr126045 -45.39 ± 3.73 -52.48 ± 9.16 64.60 ± 6.77 -6.82 ± 0.14 -40.09 ± 8.18
kni272 -65.42 ± 4.03 -66.62 ± 7.36 87.19 ± 7.35 -8.09 ± 0.13 -52.95 ± 8.45
l735524 -66.35 ± 4.65 -54.56 ± 9.65 65.63 ± 6.83 -8.44 ± 0.12 -63.73 ± 8.61
sb203238 -57.19 ± 3.44 -44.07 ± 8.28 66.78 ± 7.92 -8.05 ± 0.16 -42.53 ± 8.49
sb204144 -66.69 ± 4.68 -59.09 ± 8.04 77.62 ± 7.01 -8.85 ± 0.15 -57.02 ± 9.00
sb206343 -60.96 ± 4.29 -60.94 ± 7.91 78.06 ± 7.95 -8.36 ± 0.18 -52.20 ± 9.42
vx478 -55.39 ± 3.50 -46.59 ± 5.64 60.99 ± 6.65 -7.10 ± 0.10 -48.09 ± 7.07
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Figure 14: Docking results for the ligands: a76889, a76928, a77003 and a78791.
The left panel shows the average rmsd vs the average binding energy for MM-
GBSA calculations and the right panel shows the rmsd vs the Emodel score for
the poses from Glide docking.
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Figure 15: Docking results for the ligands: a79285, ag1343, aha001 and aha006.
The left panel shows the average rmsd vs the average binding energy for MM-
GBSA calculations and the right panel shows the rmsd vs the Emodel score for
the poses from Glide docking.
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Figure 16: Docking results for the ligands: kni272, gr126034, l735524 and
l738317. The left panel shows the average rmsd vs the average binding energy
for MM-GBSA calculations and the right panel shows the rmsd vs the Emodel
score for the poses from Glide docking.
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Figure 17: Docking results for the ligands: sb203238, sb204144, sb206343 and
vx478. The left panel shows the average rmsd vs the average binding energy for
MM-GBSA calculations and the right panel shows the rmsd vs the Emodel score
for the poses from Glide docking.
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6.2 Estrogen Receptor
6.2.1 Binding Energy Estimation
Table 7 and table 8 show the energy contributions for the standard long and mul-
tiple short trajectory approaches at 300K and 500K.
Table 7: Energy contributions for the Estrogen receptor at 300K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
gwq -29.89 ± 3.00 -29.31 ± 3.71 27.07 ± 4.09 -4.17 ± 0.15 -36.31 ± 4.27
gwr -37.34 ± 3.19 -27.26 ± 4.57 25.79 ± 4.54 -4.67 ± 0.16 -43.47 ± 4.50
sj0 -60.89 ± 4.02 -201.23 ± 9.56 192.63 ± 8.78 -6.51 ± 0.22 -76.00 ± 5.87
uom -60.82 ± 3.70 -185.09 ± 9.39 182.84 ± 8.49 -6.59 ± 0.23 -69.66 ± 6.48
x7e -32.86 ± 3.04 -38.38 ± 4.69 37.79 ± 5.39 -4.59 ± 0.16 -38.04 ± 6.12
xp1 -62.61 ± 4.12 -181.92 ± 10.51 185.55 ± 8.51 -6.72 ± 0.23 -65.70 ± 6.07
xp6 -61.98 ± 5.39 -183.52 ± 17.27 186.83 ± 14.04 -6.79 ± 0.44 -65.45 ± 8.51
xp9 -58.81 ± 3.97 -188.01 ± 9.33 185.45 ± 8.58 -6.68 ± 0.23 -68.05 ± 6.07
xpc -61.09 ± 4.08 -207.11 ± 10.14 198.26 ± 8.89 -6.60 ± 0.22 -76.54 ± 5.85
xqc -63.27 ± 3.52 -153.21 ± 8.54 159.90 ± 9.98 -6.58 ± 0.22 -63.16 ± 5.98
b1v -35.44 ± 2.94 -24.34 ± 4.52 24.83 ± 4.45 -4.49 ± 0.15 -39.44 ± 4.63
bj4 -51.73 ± 3.49 -180.26 ± 9.28 178.87 ± 8.60 -6.23 ± 0.21 -59.35 ± 6.02
fai -34.23 ± 3.14 -27.92 ± 4.52 25.82 ± 3.73 -4.66 ± 0.16 -40.98 ± 4.03
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Table 8: Energy contributions for the Estrogen receptor at 500K
Ligand VDW Elec. Elec. Nonpolar Total
desolv. desolv.
gwq -28.74 ± 3.12 -27.50 ± 5.06 27.70 ± 4.79 -4.29 ± 0.15 -32.83 ± 5.29
gwr -36.52 ± 3.41 -25.25 ± 4.68 25.36 ± 4.70 -4.72 ± 0.16 -41.14 ± 5.21
sj0 -60.00 ± 4.45 -193.25 ± 19.01 192.68 ± 14.04 -6.63 ± 0.23 -67.21 ± 8.43
uom -61.07 ± 4.17 -155.79 ± 10.15 167.10 ± 9.59 -6.64 ± 0.25 -56.40 ± 5.98
x7e -33.99 ± 3.34 -35.88 ± 4.94 36.96 ± 4.67 -4.58 ± 0.17 -37.50 ± 5.33
xp1 -61.43 ± 4.30 -170.76 ± 22.04 172.11 ± 15.93 -6.88 ± 0.25 -66.97 ± 10.23
xp6 -60.63 ± 4.38 -183.47 ± 12.59 179.90 ± 12.66 -7.01 ± 0.24 -71.21 ± 8.44
xp9 -57.90 ± 4.26 -184.15 ± 13.88 177.16 ± 11.20 -6.69 ± 0.24 -71.57 ± 7.60
xpc -58.94 ± 4.39 -166.80 ± 12.97 170.41 ± 12.55 -6.78 ± 0.24 -62.11 ± 7.06
xqc -62.10 ± 4.01 -154.48 ± 11.27 161.89 ± 13.14 -6.68 ± 0.24 -61.37 ± 6.03
b1v -34.64 ± 3.27 -23.81 ± 6.38 26.56 ± 4.99 -4.55 ± 0.16 -36.44 ± 5.94
bj4 -50.62 ± 3.58 -133.67 ± 13.24 148.78 ± 14.64 -6.41 ± 0.22 -41.92 ± 5.85
fai -37.41 ± 3.62 -22.38 ± 5.07 25.32 ± 4.99 -4.60 ± 0.17 -39.07 ± 5.75
6.2.2 Application to Docking
Figures 18 - 20 show the docking results of the Estrogen Receptor.
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Figure 18: Docking results for the ligands: B1V, XQC, FAI and GWQ. The left
panel shows the average rmsd vs the average binding energy for MM-GBSA cal-
culations and the right panel shows the rmsd vs the Emodel score for the poses
from Glide docking.
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Figure 19: Docking results for the ligands: GWR, SJ0, UOM and X7E. The left
panel shows the average rmsd vs the average binding energy for MM-GBSA cal-
culations and the right panel shows the rmsd vs the Emodel score for the poses
from Glide docking.
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Figure 20: Docking results for the ligands: XP1, XP6, XP9 and XPC. The left
panel shows the average rmsd vs the average binding energy for MM-GBSA cal-
culations and the right panel shows the rmsd vs the Emodel score for the poses
from Glide docking.
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6 Discussion
Accurate three-dimensional structures are essential for estimating binding free en-
ergy between protein and their ligands using atomistic simulations such as molecular
mechanics. In the cases where no experimentally determined structures are available,
computational methods for modeling their three-dimensional coordinates can be ap-
plied. There are various methods to do this, homology modeling currently being the
most accurate.
In the first part of this thesis we address the question of how accurate homology
models need to be in order to give useful insights into binding energy calculations. A
prerequisite to any such investigation is to have a reliable protein system in which er-
rors can be introduced and investigated. After the protein system has been verified,
homology models of decreasing back-bone accuracy are built. Finally, the effect of
incorrectly placed side-chains is investigated. The HIV-1 protease was validated as a
model system for estimating ligand binding energies. Homology models were built
for this protein based on its sequence similarity to other members of the retroviral
protease family. We found that for the HIV-1 protease we are able to obtain a very
good correlation to experimental binding energies, even for sequence similarities as
low as 32 %. Kairys et al explored the use of homology models in docking. They find
that using homologymodels for the docking can lead to as good enrichment of known
ligand comparable with using the actual crystal structure154. In addition they find
that the sequence similarity to the template used to build the homology model is not
predictive of the accuracy of the results154. This is comparable with our own findings
where binding energy calculations using homology models built on templates with
only 32 % sequence identity obtain a very good correlation to experimental data. Fur-
thermore, we found that for a correct estimation of binding free energies it is crucial
to have the side-chains placed correctly. The worst correlation to the experimental
values was found when the side-chains were modeled using only a rotamer library
without taking template conformation into account. This is in accord with McGovern
et alwho found that often small structural errors such as incorrect side-chain rotamer
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were the reason for a poor performance of some homology models155. This is also
a general observation for homology models as highlighted in recent CASP experi-
ment156. It is therefore not surprising that in our work the worst correlation to the
experimental binding energies arises from models where the only difference to the
crystal structure was the placement of side-chains. The MM-GBSA approach vali-
dated here was shown to be very promising to rank ligands and is therefore suitable
for application to protein systems where the amount of experimental data is smaller
and the quality of the structures is more diverse. However, further investigations to
narrow down specific side-chains would be of interest.
One significant limitation for the routine application of atomistic simulations in
the drug discovery process is their excessive computational cost. It is common to
dock large numbers of compounds into the binding sites of proteins and to score the
best poses obtained. These docking and scoring functions often contain a number of
approximations which can decrease the accuracy of the outcome. It would be very
valuable to have a fast and accurate scoring function to calculating the interactions
between proteins and ligands accurately. One way to achieve more accurate scoring
is to use conformational sampling and force field based scoring functions, but their
long computational times make them less suitable for dealing with the large number
of compounds that is required for drug discovery. For the second part of the the-
sis we modify the previously validated MM-GBSA approach in order to reduce the
computational time needed to estimate binding energies. A novel method is devel-
oped that allows multiple short molecular dynamics simulations to be run on a grid
of distributed computers (PC Grid) instead of the traditional way of running a single
long molecular dynamics simulation. We find that using this multiple short molecu-
lar dynamics approach we are able to obtain a very good correlation to experimental
binding free energies for the HIV-1 model system. This methodology was found to
shorten the computational time needed from around 4 days with the traditional ap-
proach to around 2 days for the multiple short approach. We found that the multiple
short molecular dynamics simulation approach at 300K samples very similar confor-
mations and energies as the traditional long approach. By raising the temperature
to 500K the multiple short and traditional long approaches sample slightly different
conformations but not enough to have an impact on the energies.
A major part of analysis is to find methods that distinguish between characteristics
of a system, for example conformational variability. There are various ways that have
been developed to investigate differences in sampling and structures. Monticelli et
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al pre-defined certain conformational state and then compared how they were popu-
lated between different simulation approaches107. An interesting method to analyze
the structural differences and similarities in alternative structural models based on C
α or side chain centroid variability157. However, we found this method is ill adapted
to the large scale analysis needed here. A common method to estimate the conforma-
tional space sampled is principle component analysis, which reduces dimensionality
to identify major contributions to the atomic displacements104.
Clustering is a popular tool to divide a large dataset into subsets based on a given
criteria. These subsets can then be analyzed further to find unique features that char-
acterize specificities of the subset. The advantage of using clustering tools is that only
one property is needed as criteria, but in addition information can be inferred from
other contributions. In this work a novel analysis was developed that is specific to the
protein-ligand binding residues. This analysis is based on defining a cluster metric,
which in our case is either the per-residue binding energy contribution or per-residue
distance RMSD. The values for each of the metrics for all residues in the binding
pocket then give a fingerprint of the interaction in a particular frame of the simula-
tion. These fingerprints for all frames of simulations that are being compared can
then be clustered to identify subsets that share common qualities. From these subsets
we can then identify the residues that are specific for each subset by using a modified
version of the proteinkey analysis153.
A prerequisite for using the MM-GBSA approach on other systems is obtaining pa-
rameters for the ligands that are not described in the CHARMM force field91. We
successfully automated the Antechamber program to generate parameters suitable
for calculations using CHARMM and validated the results. In order to test if the MM-
GBSA method is applicable to other protein systems, we applied the same methodol-
ogy to experimental ligand binding data to the estrogen receptor β. Using this protein
system we found the same, which is that by using the multiple short molecular dy-
namics approach we are able to obtain very good correlation to experimental binding
energies. This is comparable to previous findings where it has been suggested that
a good sampling of the conformational space of protein can be achieved by running
multiple short trajectories instead of a single long trajectory101,102.
These findings of reduced computational time and transferability to the estrogen
receptor encouraged us to apply our relatively fast and accurate scoring function to
the question of scoring conformations of ligands derived from docking simulations.
The objective is twofold; to see if the docked pose can be improved by molecular sim-
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ulation and to see if a better ranking of the poses can be obtainedwith amore accurate
scoring function. For the docking of ligands in the HIV-1 protease the MM-GBSA ap-
proach is able to improve the ranking of the poses and distinguish between poses
that are similar to the actual crystal structure pose and those that are not. There are
however exceptions from this, cases where low rmsd poses and those with very high
rmsd all obtain very favorable binding energies. This is explained by the ability of the
MMmethod to optimize energetically favorable interactions to the protein in spite of
a large overall rmsd difference. In a study by Nervall et al, a series of HIV-1 reverse
transcriptase inhibitors was cross-docked into a non-native crystal structure. They
were able to distinguish between correct binding mode and an incorrect one which
displayed a flipped heterocyclic group using molecular dynamics simulation and the
LIE method158. Graves et al found that rescoring docked poses with MMGBSA better
distinguished known ligands from known decoys as compared to the scoring func-
tions159. They also found that rescoring introduced new false positives in spite of
rescuing docking false positives.
However, for the docking of ligands to the estrogen receptor we didn’t see improve-
ment in the ranking. It has been suggested that alchemical relative free energy meth-
ods are outperforming approximate methods such as MM-GBSA in ligand binding
studies to the estrogen receptor80,160. Since the computation time of such methods is
considerable it is worthwhile to identify limitations of MM-GBSA in order to develop
a reliable universal method.
The MM-GBSA method in combination to the clustering analysis has the potential
to identify a small number of protein residues that are necessary to obtain favorable
binding free energies to a docked compound. Once these residues are identified they
can be used in flexible docking to increase accuracy but reduce the time needed if the
whole binding site was allowed to stay flexible. However, there are some limitations
highlighted with its inability to improve the ranking of the estrogen receptor ligands.
These limitations have to be investigated further to identify their source. Further
studies with different protein systems are required to elaborate, if and for which sys-
tems MM-GBSA based methods can provide significant improvements over simple
scoring functions for ligand binding.
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This thesis has addressed some important limitations of the applications of computa-
tional modeling methods in the drug discovery process. For the homology modeling
aspects, we and others have shown that even models with low sequence similarity
can be used to obtain very good correlation to experimental data. However, we only
looked at the HIV-1 protease which belongs to a very structurally conserved family.
It would be of interest to look into other less favorable cases. Of even more interest
would be to investigate in more detail what exactly is the limitation of the side-chain
accuracy, to narrow it down to specific interactions.
We have successfully reduced the computational time required for MM-GBSA cal-
culations by using a multiple short trajectory approach for the conformational sam-
pling. This method has also been shown to give rise to good correlation to exper-
imental data. In its applications to docked poses it is able to distinguish between
good and bad poses for the HIV-1 protease but is unable to improve the poses signif-
icantly. It would be of great interest to look into improving the poses by alternative
means of sampling. The MM-GBSA inability of improving the ranking of the ligands
for estrogen receptor needs detailed analysis to answer the question whether it is a
limitation of the scoring function or the docking program. In order to do that, more
systems have to be included and analyzed to find the weaknesses of the approach.
Ultimately it is the goal to have a method that not only will improve the pose obtain
from docking but in addition correctly predict the binding energy. In addition this
method would need to be transferable between different protein systems and take
solvation, entropy and allosteric effects into account. Finally it would be valuable to
have an analysis pipeline suitable for non experts where top ranking hits from dock-
ing runs could be analyzed in more detail.
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